• Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
• The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
• Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
• As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
• The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

• Oncotelic Therapeutics is focused on advancing technologies designed to bypass or overcome BBB limitations.
• The global burden of Alzheimer’s disease and related dementias is increasing at an unprecedented rate.
• Beyond chronic diseases, CNS drug delivery is also a critical factor in biodefense and national security.
• As traditional drug-delivery approaches continue to face limitations, alternative methods designed to bypass the BBB, such as those being developed by Oncotelic, are gaining increasing attention.
• The future of CNS therapeutics is increasingly centered on platform-based solutions rather than single-drug strategies.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

• As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine.
• SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.
• The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.
• Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.
• SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.

For further information about SureNano Science Ltd., visit the SureNano Science profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

• As the global obesity crisis continues, GLP-1 receptor agonists have rapidly emerged as one of the most important therapeutic breakthroughs in metabolic medicine.
• SureNano Science is advancing GEP-44 as a next-generation metabolic therapy intended to improve upon limitations associated with first-generation GLP-1 drugs.
• The global GLP-1 market could total more than $200 billion by 2035 as patient adoption expands and broader therapeutic applications emerge.
• Beyond therapeutic innovation itself, SureNano Science is also pursuing differentiated drug-delivery technologies designed to improve patient accessibility and adherence.
• SureNano Science is also evaluating early-stage opportunities that could broaden the long-term scope of its therapeutic and delivery technology portfolio, including exposure to Ibogaine.

For further information about SureNano Science Ltd., visit the SureNano Science profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

• The biotechnology sector is evolving from a model centered on long-term R&D investment into one where scientific advancement can be reflected as measurable financial value.
• As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization.
• The rise of fair-value accounting in biotechnology is enabling companies to provide more transparent and timely representations of asset value.
• Institutional investors are increasingly recognizing clinical-stage biotech assets as investable opportunities, even in the absence of current revenue.
• Oncotelic Therapeutics operates directly within this convergence, combining oncology-focused drug development with AI-enabled platforms and strategic manufacturing exposure.

To read the full publication, visit https://ibn.fm/A0b3u

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

About BioMedWire

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

• The biotechnology sector is evolving from a model centered on long-term R&D investment into one where scientific advancement can be reflected as measurable financial value.
• As drug candidates advance through clinical development, their value increases significantly due to rising probabilities of success and proximity to commercialization.
• The rise of fair-value accounting in biotechnology is enabling companies to provide more transparent and timely representations of asset value.
• Institutional investors are increasingly recognizing clinical-stage biotech assets as investable opportunities, even in the absence of current revenue.
• Oncotelic Therapeutics operates directly within this convergence, combining oncology-focused drug development with AI-enabled platforms and strategic manufacturing exposure.

To read the full publication, visit https://ibn.fm/A0b3u

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

About BioMedWire

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

To begin the interview, Dr. Schaber addressed the upcoming interim analysis of the company’s Phase 3 FLASH2 study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (“CTCL”).

“Well, first with that interim analysis conducted by the Data Monitoring Committee (“DMC”), which all remain blinded to the outcome except for the DMC, we’ll be looking at safety and making sure that the drug is safe. We have no reason to believe that it is not — it’s shown safety in every study we’ve ever done,” he said. “The study will also evaluate efficacy, primarily around the primary endpoint… The read will essentially determine whether we continue enrolling to 80 patients, stop early for overwhelming efficacy or re-estimate the sample size if the power calculations were slightly off. After all the work we’ve done, I believe the higher likelihood is either a ‘stop early’ or continuing to 80, and that’s what we’re looking for this quarter.”

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

To begin the interview, Dr. Schaber addressed the upcoming interim analysis of the company’s Phase 3 FLASH2 study evaluating HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma (“CTCL”).

“Well, first with that interim analysis conducted by the Data Monitoring Committee (“DMC”), which all remain blinded to the outcome except for the DMC, we’ll be looking at safety and making sure that the drug is safe. We have no reason to believe that it is not — it’s shown safety in every study we’ve ever done,” he said. “The study will also evaluate efficacy, primarily around the primary endpoint… The read will essentially determine whether we continue enrolling to 80 patients, stop early for overwhelming efficacy or re-estimate the sample size if the power calculations were slightly off. After all the work we’ve done, I believe the higher likelihood is either a ‘stop early’ or continuing to 80, and that’s what we’re looking for this quarter.”

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

• Central nervous system disorders such as brain cancer, Alzheimer’s Disease, Parkinson’s Disease and others represent one of the largest and most challenging therapeutic categories in modern medicine.
• The convergence ance of CNS and oncology makes Oncotelic’s update on expanding international IP coverage for OT-101 even more impactful.
• Oncotelic Therapeutics’ focus on delivery approaches relevant to CNS and oncology aligns with the industry’s direction.
• Oncotelic Therapeutics’ development of OT-101 demonstrates its advanced R&D capabilities and innovative repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research.
• Oncotelic Therapeutics positions itself with a diversified portfolio spanning oncology-focused therapies, CNS indications and delivery technologies.

Big Pharma’s Shift Toward Proven Assets

Biopharma dealmaking has increasingly centered on external innovation, licensing, and acquisitions of assets that demonstrate clinical validation. Strategic analyses from McKinsey & Company describe continued reliance on partnerships and acquisitions to replenish pipelines as internal R&D productivity challenges persist. Similarly, Deloitte’s life sciences M&A outlook highlights ongoing selectivity and capital discipline, encouraging companies to prioritize assets with clearer development paths and measurable progress toward commercialization.

This strategic pivot reflects economic realities. Drug-development timelines remain long and costly, and investors have increasingly favored programs that demonstrate human safety or efficacy signals. Late-stage assets can reduce scientific uncertainty because clinical data provides clearer insight into safety profiles, dosing parameters, and potential regulatory pathways. As a result, companies nearing pivotal studies or late clinical phases may attract greater interest from acquirers seeking faster paths to market entry.

Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing innovation, while CNS disorders represent some of the most significant unmet medical needs globally. Assets that bridge these areas may offer differentiated positioning, especially when they address complex biological pathways or delivery challenges that have historically limited therapeutic success.

Platforms supported by existing human data also carry valuation advantages. Programs that demonstrate clinical activity provide tangible milestones that investors can evaluate, reducing uncertainty compared with early discovery-stage platforms. This dynamic is contributing to growing attention toward companies holding clinical-stage portfolios rather than single preclinical assets.

Oncotelic Therapeutics fits this strategic profile through its clinical-stage pipeline focused on oncology and CNS-related targets. A clinical-stage biopharmaceutical developer, the company is pursuing therapies for cancer and other serious conditions. Oncotelic’s programs, including those targeting TGF-β signaling and delivery-focused approaches, align with the broader industry emphasis on validated mechanisms and diversified development strategies.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire Austin, Texas www.BioMedWire.com 512.354.7000 Office Editor@BioMedWire.com

BioMedWire is powered by IBN

• Central nervous system disorders such as brain cancer, Alzheimer’s Disease, Parkinson’s Disease and others represent one of the largest and most challenging therapeutic categories in modern medicine.
• The convergence ance of CNS and oncology makes Oncotelic’s update on expanding international IP coverage for OT-101 even more impactful.
• Oncotelic Therapeutics’ focus on delivery approaches relevant to CNS and oncology aligns with the industry’s direction.
• Oncotelic Therapeutics’ development of OT-101 demonstrates its advanced R&D capabilities and innovative repositioning approach by exploring applications across oncology indications supported by mechanistic rationale and prior clinical research.
• Oncotelic Therapeutics positions itself with a diversified portfolio spanning oncology-focused therapies, CNS indications and delivery technologies.

Big Pharma’s Shift Toward Proven Assets

Biopharma dealmaking has increasingly centered on external innovation, licensing, and acquisitions of assets that demonstrate clinical validation. Strategic analyses from McKinsey & Company describe continued reliance on partnerships and acquisitions to replenish pipelines as internal R&D productivity challenges persist. Similarly, Deloitte’s life sciences M&A outlook highlights ongoing selectivity and capital discipline, encouraging companies to prioritize assets with clearer development paths and measurable progress toward commercialization.

This strategic pivot reflects economic realities. Drug-development timelines remain long and costly, and investors have increasingly favored programs that demonstrate human safety or efficacy signals. Late-stage assets can reduce scientific uncertainty because clinical data provides clearer insight into safety profiles, dosing parameters, and potential regulatory pathways. As a result, companies nearing pivotal studies or late clinical phases may attract greater interest from acquirers seeking faster paths to market entry.

Oncology and CNS programs have emerged as particularly strategic targets within this framework. Oncology continues to dominate pharmaceutical pipelines due to large commercial markets and ongoing innovation, while CNS disorders represent some of the most significant unmet medical needs globally. Assets that bridge these areas may offer differentiated positioning, especially when they address complex biological pathways or delivery challenges that have historically limited therapeutic success.

Platforms supported by existing human data also carry valuation advantages. Programs that demonstrate clinical activity provide tangible milestones that investors can evaluate, reducing uncertainty compared with early discovery-stage platforms. This dynamic is contributing to growing attention toward companies holding clinical-stage portfolios rather than single preclinical assets.

Oncotelic Therapeutics fits this strategic profile through its clinical-stage pipeline focused on oncology and CNS-related targets. A clinical-stage biopharmaceutical developer, the company is pursuing therapies for cancer and other serious conditions. Oncotelic’s programs, including those targeting TGF-β signaling and delivery-focused approaches, align with the broader industry emphasis on validated mechanisms and diversified development strategies.

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire Austin, Texas www.BioMedWire.com 512.354.7000 Office Editor@BioMedWire.com

BioMedWire is powered by IBN

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Giorgio R. Saumat, Chairman and CEO of Earth Science Tech Inc. (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential operating businesses.

To begin the interview, Saumat outlined Earth Science Tech’s core business model and how the company has structured its healthcare operations.

“Earth Science Tech, at this time, is a strategic holding company with core assets in healthcare, mostly compounding pharmaceuticals and online telehealth,” he said. “We are creating a vertically integrated healthcare company. From the marketing side we have Peaks Curative, our online telehealth subsidiary, all the way through Mister Meds and RxCompoundStore.com that fulfill the patient.”

He then discussed the company’s financial discipline and capital markets positioning, emphasizing its balance sheet strength and preparation for a potential uplist.

“We have not had any need to tap the capital markets in the last three years. The company is strong on a cash flow basis and has a very strong balance sheet… There are not many OTC companies that are cash flow positive with positive EPS and a strong balance sheet as we have. We have very little debt. We’re preparing the company for a proper uplist, and I think that’s going to help with our liquidity as the market finally gets to know who we are and gets our story out.”

Looking ahead, Saumat highlighted the company’s profitability, diversification strategy and readiness to scale.

“We are a profitable company, and our earnings and revenue are growing. We made some diversification moves in 2025, and I think we’re going to be building on those throughout the rest of 2026… There are a lot of companies out there much larger than we are that wish they could be in the position that we’re in. Luckily, we’re small and nimble, so we were able to put it together. Now it’s time to scale it, which is what we’re headed toward.”

Join IBN’s Carmel Fisher for a conversation with Giorgio R. Saumat, Chairman and CEO of Earth Science Tech, as he discusses the company’s vertically integrated healthcare model, financial strength and pathway toward scaled growth.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Earth Science Tech Inc.

Earth Science Tech Inc. is a diversified holding company focused on the health and wellness sector. Through its wholly-owned subsidiaries, ETST operates a vertically integrated portfolio that includes high-quality compounding pharmacies, telemedicine platforms, and targeted healthcare facilities. The company currently owns RxCompoundStore.com and Mister Meds, two licensed compounding pharmacies providing sterile and non-sterile medications across a growing network of U.S. states. These operations are supported by Peaks Curative and Doconsultation.com, telemedicine platforms that connect patients with providers for personalized care.

Beyond healthcare, ETST manages Avenvi, its real estate and asset management arm, and MagneChef, a direct-to-consumer brand leveraging proprietary IP for innovative kitchen products. The company is also committed to social responsibility through the Earth Science Foundation, a non-profit dedicated to assisting patients with prescription costs.

For more information, visit the company’s website at www.EarthScienceTech.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Giorgio R. Saumat, Chairman and CEO of Earth Science Tech Inc. (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential operating businesses.

To begin the interview, Saumat outlined Earth Science Tech’s core business model and how the company has structured its healthcare operations.

“Earth Science Tech, at this time, is a strategic holding company with core assets in healthcare, mostly compounding pharmaceuticals and online telehealth,” he said. “We are creating a vertically integrated healthcare company. From the marketing side we have Peaks Curative, our online telehealth subsidiary, all the way through Mister Meds and RxCompoundStore.com that fulfill the patient.”

He then discussed the company’s financial discipline and capital markets positioning, emphasizing its balance sheet strength and preparation for a potential uplist.

“We have not had any need to tap the capital markets in the last three years. The company is strong on a cash flow basis and has a very strong balance sheet… There are not many OTC companies that are cash flow positive with positive EPS and a strong balance sheet as we have. We have very little debt. We’re preparing the company for a proper uplist, and I think that’s going to help with our liquidity as the market finally gets to know who we are and gets our story out.”

Looking ahead, Saumat highlighted the company’s profitability, diversification strategy and readiness to scale.

“We are a profitable company, and our earnings and revenue are growing. We made some diversification moves in 2025, and I think we’re going to be building on those throughout the rest of 2026… There are a lot of companies out there much larger than we are that wish they could be in the position that we’re in. Luckily, we’re small and nimble, so we were able to put it together. Now it’s time to scale it, which is what we’re headed toward.”

Join IBN’s Carmel Fisher for a conversation with Giorgio R. Saumat, Chairman and CEO of Earth Science Tech, as he discusses the company’s vertically integrated healthcare model, financial strength and pathway toward scaled growth.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 20 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Earth Science Tech Inc.

Earth Science Tech Inc. is a diversified holding company focused on the health and wellness sector. Through its wholly-owned subsidiaries, ETST operates a vertically integrated portfolio that includes high-quality compounding pharmacies, telemedicine platforms, and targeted healthcare facilities. The company currently owns RxCompoundStore.com and Mister Meds, two licensed compounding pharmacies providing sterile and non-sterile medications across a growing network of U.S. states. These operations are supported by Peaks Curative and Doconsultation.com, telemedicine platforms that connect patients with providers for personalized care.

Beyond healthcare, ETST manages Avenvi, its real estate and asset management arm, and MagneChef, a direct-to-consumer brand leveraging proprietary IP for innovative kitchen products. The company is also committed to social responsibility through the Earth Science Foundation, a non-profit dedicated to assisting patients with prescription costs.

For more information, visit the company’s website at www.EarthScienceTech.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 20+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

• Cutaneous T-cell lymphoma (“CTCL”) is a rare subtype of non-Hodgkin’s lymphoma that disproportionately affects older adults.
• SNGX’s confirmatory FLASH2 study represents the final major step toward potential worldwide marketing approval for HyBryte.
• The first FLASH phase 3 trial demonstrated statistically significant efficacy, establishing a strong foundation for the confirmatory FLASH2 study.
• An ongoing investigator-initiated study at the University of Pennsylvania is providing additional real-world insight into HyBryte’s effectiveness.
• Beyond its immediate CTCL application, HyBryte’s life-cycle management strategy includes opportunities to expand the treatment’s reach and value.

A Diagnostic Challenge Meets Policy Change

Rare diseases have long been difficult to diagnose, but older adults often face a uniquely complex path. Many rare disease symptoms overlap with common age-related conditions such as dermatologic changes, cognitive decline, chronic inflammation or fatigue, making misdiagnosis a persistent problem. According to the National Organization for Rare Disorders (“NORD”), patients often go five to seven years before receiving an accurate diagnosis. This diagnostic delay can worsen outcomes, delay treatment, and create emotional and financial stress, particularly for older adults who frequently see multiple specialists without definitive answers.

Symptoms of rare diseases can also mimic those associated with normal aging. For example, skin changes that may appear benign can mask early manifestations of CTCL. Neurological or systemic symptoms related to rare autoimmune or genetic disorders may be mistaken for more common issues such as arthritis or dementia. This overlap complicates clinical assessments and often forces physicians to rely on advanced testing or second opinions to reach a conclusive diagnosis.

For more information about Soligenix Inc., visit the Soligenix Profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

• Cutaneous T-cell lymphoma (“CTCL”) is a rare subtype of non-Hodgkin’s lymphoma that disproportionately affects older adults.
• SNGX’s confirmatory FLASH2 study represents the final major step toward potential worldwide marketing approval for HyBryte.
• The first FLASH phase 3 trial demonstrated statistically significant efficacy, establishing a strong foundation for the confirmatory FLASH2 study.
• An ongoing investigator-initiated study at the University of Pennsylvania is providing additional real-world insight into HyBryte’s effectiveness.
• Beyond its immediate CTCL application, HyBryte’s life-cycle management strategy includes opportunities to expand the treatment’s reach and value.

A Diagnostic Challenge Meets Policy Change

Rare diseases have long been difficult to diagnose, but older adults often face a uniquely complex path. Many rare disease symptoms overlap with common age-related conditions such as dermatologic changes, cognitive decline, chronic inflammation or fatigue, making misdiagnosis a persistent problem. According to the National Organization for Rare Disorders (“NORD”), patients often go five to seven years before receiving an accurate diagnosis. This diagnostic delay can worsen outcomes, delay treatment, and create emotional and financial stress, particularly for older adults who frequently see multiple specialists without definitive answers.

Symptoms of rare diseases can also mimic those associated with normal aging. For example, skin changes that may appear benign can mask early manifestations of CTCL. Neurological or systemic symptoms related to rare autoimmune or genetic disorders may be mistaken for more common issues such as arthritis or dementia. This overlap complicates clinical assessments and often forces physicians to rely on advanced testing or second opinions to reach a conclusive diagnosis.

For more information about Soligenix Inc., visit the Soligenix Profile.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

This release has been disseminated on behalf of Oncotelic Therapeutics, which may include a paid advertisement.

NetworkNewsWire Editorial Coverage: The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.’s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals real-world momentum behind this vision, showing how innovation in delivery science can unlock new value across multiple drug candidates. Oncotelic Therapeutics is focused on making its mark in the oncology treatment space, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)

• The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration.
• Oncotelic Therapeutics’ Deciparticle technology directly addresses this effective drug-delivery need with a modular, ultra-high-efficiency nanomedicine delivery engine.
• Sapu-003 has now advanced into first-in-human clinical trials in Australia, marking a pivotal moment for the platform’s external validation.
• The projected $500-billion-plus nanomedicine market by 2032 is anchored more by delivery innovation than by new molecular discoveries.
• Deciparticle-enabled therapies could deliver materially more effective treatment with lower toxicity.

The Global Shift Toward Smarter Drug Delivery

The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Many promising oncology drugs fail not because the therapy lacks biological power, but because the body absorbs only a fraction of the intended dose. Conventional oral and IV therapies struggle with poor solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong.

As a result, the industry is increasingly prioritizing drug-delivery innovation as much as drug discovery itself. Nanomedicine, the engineering of sub-200-nanometer drug carriers, is rapidly becoming the leading solution to address absorption inefficiencies and off-target toxicity. These platforms are designed not only to protect the drug from premature degradation but also control its release and guide it more precisely to tumor environments. Leading market research estimates that the global nanomedicine market could surpass $500 billion by 2032, driven by oncology-focused breakthroughs that materially improve drug absorption and targeting.

Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting to delivery-optimizing, companies that control best-in-class bioavailability engines are positioned to redefine the competitive landscape.

To view the full publication, visit https://ibn.fm/oNe26

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

NetworkNewsWire Editorial Coverage: The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.’s (OTCQB: OTLC) (profile) Deciparticle(TM) platform exemplifies this shift. It offers a novel approach to increase the bioavailability and therapeutic index of existing cancer drugs, potentially transforming underperforming compounds into next-generation therapies. The recent advancement of Sapu-003 into human trials signals real-world momentum behind this vision, showing how innovation in delivery science can unlock new value across multiple drug candidates. Oncotelic Therapeutics is focused on making its mark in the oncology treatment space, along with other innovative leaders such as IO Biotech Inc. (NASDAQ: IOBT), Novartis AG (NYSE: NVS), Bicara Therapeutics Inc. (NASDAQ: BCAX) and Pfizer Inc. (NYSE: PFE)

• The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration.
• Oncotelic Therapeutics’ Deciparticle technology directly addresses this effective drug-delivery need with a modular, ultra-high-efficiency nanomedicine delivery engine.
• Sapu-003 has now advanced into first-in-human clinical trials in Australia, marking a pivotal moment for the platform’s external validation.
• The projected $500-billion-plus nanomedicine market by 2032 is anchored more by delivery innovation than by new molecular discoveries.
• Deciparticle-enabled therapies could deliver materially more effective treatment with lower toxicity.

The Global Shift Toward Smarter Drug Delivery

The pharmaceutical industry is entering an inflection point driven by the recognition that highly potent cancer drugs are only as effective as their ability to reach tumors with sufficient concentration. Many promising oncology drugs fail not because the therapy lacks biological power, but because the body absorbs only a fraction of the intended dose. Conventional oral and IV therapies struggle with poor solubility, steep metabolism and imprecise biodistribution, forcing high doses and resulting in systemic toxicity. This is especially problematic in mTOR inhibitors, kinase inhibitors, and vascular-disrupting agents, where dose-limiting toxicity can halt development even when preclinical data were strong.

As a result, the industry is increasingly prioritizing drug-delivery innovation as much as drug discovery itself. Nanomedicine, the engineering of sub-200-nanometer drug carriers, is rapidly becoming the leading solution to address absorption inefficiencies and off-target toxicity. These platforms are designed not only to protect the drug from premature degradation but also control its release and guide it more precisely to tumor environments. Leading market research estimates that the global nanomedicine market could surpass $500 billion by 2032, driven by oncology-focused breakthroughs that materially improve drug absorption and targeting.

Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies and RNA therapies. These new formulations are not simply incremental improvements; they can transform once-marginal drugs into category-changing assets. As precision medicine evolves from mutation-targeting to delivery-optimizing, companies that control best-in-class bioavailability engines are positioned to redefine the competitive landscape.

To view the full publication, visit https://ibn.fm/oNe26

For further information about Oncotelic Therapeutics Inc., visit the Oncotelic Therapeutics profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

• Izotropic Corporation has advanced its plan to commercialize IzoView, a dedicated breast CT scanner purpose-built to address dense breast imaging, a high-priority and underserved segment.
• One of Izotropic’s key selling points is that IzoView is engineered for economic scalability and extensibility.
• Izotropic’s strategy relies on a proprietary AI image reconstruction algorithm, trained over 15 years of specialized breast CT data and held as a trade secret.
• Izotropic’s vision for IzoView extends beyond imaging hardware; it is structured to become a node within the larger AI-enabled diagnostic ecosystem.
• According to analysts, the global breast imaging market is projected to grow at ~8.6% CAGR between 2023 and 2030, reaching approximately $9 billion by 2030.

AI and 3D Imaging: The New Frontiers of Detection

The convergence of AI and three-dimensional (“3D”) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the physical compression required to visualize internal structures.

In dense breast tissue, present in more than one-half of women, lesions can be obscured or distorted, leading to reduced sensitivity and delayed detection. Research confirms that dense fibroglandular tissue can mask or mimic breast cancers, thereby lowering diagnostic accuracy and increasing the risk of missed cases, with one study reporting that mammography performance declines significantly in dense breasts, as overlapping tissue often conceals malignancies.

The emergence of AI-driven image reconstruction and analysis now offers a transformative solution to these long-standing challenges. Advanced algorithms can enhance contrast, reduce image noise and identify subtle patterns invisible to human interpretation. AI-based methods have also been shown to improve CT image quality while maintaining or reducing radiation dose, producing clearer and safer diagnostic results. In breast imaging specifically, recent reviews highlight that deep learning systems can augment or even match radiologist performance in lesion detection, segmentation and classification, particularly in dense tissue or early-stage disease.

This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a broader shift toward intelligent diagnostics capable of generating and interpreting 3D data simultaneously. Radiology experts anticipate that AI will continue to revolutionize accuracy and efficiency across medical imaging, supporting clinicians in faster and more reliable decision-making.

Within this environment, Izotropic’s IzoView Breast CT Imaging System is designed to operate between digital breast tomosynthesis and MRI, combining high-resolution volumetric imaging with proprietary AI reconstruction technology. Its trade-secret algorithm, built on more than a decade of specialized breast CT data, and its potential integration with future computer-aided diagnosis (“CADx”) tools position IzoView squarely at the frontier of AI-empowered breast cancer detection.

To view the full publication, visit https://ibn.fm/33JVK

For further information about Izotropic Corporation, please visit the Izotropic Corporation profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

• Izotropic Corporation has advanced its plan to commercialize IzoView, a dedicated breast CT scanner purpose-built to address dense breast imaging, a high-priority and underserved segment.
• One of Izotropic’s key selling points is that IzoView is engineered for economic scalability and extensibility.
• Izotropic’s strategy relies on a proprietary AI image reconstruction algorithm, trained over 15 years of specialized breast CT data and held as a trade secret.
• Izotropic’s vision for IzoView extends beyond imaging hardware; it is structured to become a node within the larger AI-enabled diagnostic ecosystem.
• According to analysts, the global breast imaging market is projected to grow at ~8.6% CAGR between 2023 and 2030, reaching approximately $9 billion by 2030.

AI and 3D Imaging: The New Frontiers of Detection

The convergence of AI and three-dimensional (“3D”) medical imaging marks a turning point in diagnostic medicine. While traditional mammography has been a life-saving screening tool for decades, it is inherently constrained by its two-dimensional projection format and the physical compression required to visualize internal structures.

In dense breast tissue, present in more than one-half of women, lesions can be obscured or distorted, leading to reduced sensitivity and delayed detection. Research confirms that dense fibroglandular tissue can mask or mimic breast cancers, thereby lowering diagnostic accuracy and increasing the risk of missed cases, with one study reporting that mammography performance declines significantly in dense breasts, as overlapping tissue often conceals malignancies.

The emergence of AI-driven image reconstruction and analysis now offers a transformative solution to these long-standing challenges. Advanced algorithms can enhance contrast, reduce image noise and identify subtle patterns invisible to human interpretation. AI-based methods have also been shown to improve CT image quality while maintaining or reducing radiation dose, producing clearer and safer diagnostic results. In breast imaging specifically, recent reviews highlight that deep learning systems can augment or even match radiologist performance in lesion detection, segmentation and classification, particularly in dense tissue or early-stage disease.

This integration of AI with volumetric imaging technologies, such as tomosynthesis, MRI and dedicated breast CT, signals a broader shift toward intelligent diagnostics capable of generating and interpreting 3D data simultaneously. Radiology experts anticipate that AI will continue to revolutionize accuracy and efficiency across medical imaging, supporting clinicians in faster and more reliable decision-making.

Within this environment, Izotropic’s IzoView Breast CT Imaging System is designed to operate between digital breast tomosynthesis and MRI, combining high-resolution volumetric imaging with proprietary AI reconstruction technology. Its trade-secret algorithm, built on more than a decade of specialized breast CT data, and its potential integration with future computer-aided diagnosis (“CADx”) tools position IzoView squarely at the frontier of AI-empowered breast cancer detection.

To view the full publication, visit https://ibn.fm/33JVK

For further information about Izotropic Corporation, please visit the Izotropic Corporation profile.

For more information, please visit www.NetworkNewsWire.com

Please view full terms of use and disclaimers on the NNW website applicable to all content provided by NNW, wherever published or re-published: http://www.nnw.fm/Disclaimer

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

Dr. Trieu kicked off the conversation with a major update on Oncotelic’s latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform.

“We’re very excited about the Sapu-003 approval to start a Phase 1 clinical trial,” he said. “This is a drug that targets breast cancer specifically… Breast cancer is roughly $30–40 billion in terms of addressable market size and [is forecast to] grow beyond that to roughly $50 billion by 2030. We feel that this drug candidate really has a lot of potential to change how breast cancer patients get treated and improve on Afinitor®, which is already a blockbuster drug.”

He then explained how the company’s Deciparticle™ nanomedicine platform addresses one of the biggest limitations of current mTOR inhibitors—poor bioavailability.

“If administered orally, only 10% of Afinitor® gets into the tissues, into the tumor. Bioavailability is low, so patients have to really take a lot of the drug to get enough in to kill the tumor, exposing themselves to gastric toxicity. With Sapu-003, we inject the drug directly, so 100% of the drug goes straight to the tumor… It kills off the tumor, and [there’s] a very minimal amount in the gut. You don’t have that gut toxicity that comes with oral administration.”

Looking ahead, Dr. Trieu outlined an aggressive development timeline for Sapu-003 and the broader Deciparticle™ pipeline.

“Our focus has always been to accelerate development as quickly as we can to get to market approval… This is an example where we took it from concept to clinical trial in less than one year… We anticipate finishing Phase 1 fairly quickly and then moving to Phase 3. So, within 2–3 years, we would like to have this drug product approved, which is faster than traditional drug development, where you’re looking at 10–15 years for approval.”

Join IBN’s Carmel Fisher for a follow-up conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, as he shares how Sapu-003 and the Deciparticle™ platform are reshaping the company’s approach to oncology innovation and clinical execution.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features the return of Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

Dr. Trieu kicked off the conversation with a major update on Oncotelic’s latest clinical milestone: the advancement of Sapu-003, a novel IV formulation of everolimus (Afinitor®) built on Oncotelic’s proprietary Deciparticle™ platform.

“We’re very excited about the Sapu-003 approval to start a Phase 1 clinical trial,” he said. “This is a drug that targets breast cancer specifically… Breast cancer is roughly $30–40 billion in terms of addressable market size and [is forecast to] grow beyond that to roughly $50 billion by 2030. We feel that this drug candidate really has a lot of potential to change how breast cancer patients get treated and improve on Afinitor®, which is already a blockbuster drug.”

He then explained how the company’s Deciparticle™ nanomedicine platform addresses one of the biggest limitations of current mTOR inhibitors—poor bioavailability.

“If administered orally, only 10% of Afinitor® gets into the tissues, into the tumor. Bioavailability is low, so patients have to really take a lot of the drug to get enough in to kill the tumor, exposing themselves to gastric toxicity. With Sapu-003, we inject the drug directly, so 100% of the drug goes straight to the tumor… It kills off the tumor, and [there’s] a very minimal amount in the gut. You don’t have that gut toxicity that comes with oral administration.”

Looking ahead, Dr. Trieu outlined an aggressive development timeline for Sapu-003 and the broader Deciparticle™ pipeline.

“Our focus has always been to accelerate development as quickly as we can to get to market approval… This is an example where we took it from concept to clinical trial in less than one year… We anticipate finishing Phase 1 fairly quickly and then moving to Phase 3. So, within 2–3 years, we would like to have this drug product approved, which is faster than traditional drug development, where you’re looking at 10–15 years for approval.”

Join IBN’s Carmel Fisher for a follow-up conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, as he shares how Sapu-003 and the Deciparticle™ platform are reshaping the company’s approach to oncology innovation and clinical execution.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope.

“Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.”

He then discussed how Oncotelic’s development approach sets the company apart in the biotech space.

“What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.”

Looking ahead, Dr. Trieu outlined the key inflection points investors should watch.

“Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.”

Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.

To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope.

“Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.”

He then discussed how Oncotelic’s development approach sets the company apart in the biotech space.

“What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.”

Looking ahead, Dr. Trieu outlined the key inflection points investors should watch.

“Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.”

Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Oncotelic Therapeutics

Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.

In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For more information, visit the company’s website at www.Oncotelic.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies.

Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy.

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For further information, please visit the company’s website at www.Oncotelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a career defined by innovation and successful translation of science into practice. He has filed more than 500 patent applications and holds 75 issued patents — credentials that few industry executives can match. These patents cover a wide array of drug-development strategies, spanning oncology, immunotherapy and nanomedicine, reflecting his deep engagement in pioneering technologies.

Among Trieu’s most significant achievements has been his role in developing Abraxane(R), a nanotechnology-based formulation of paclitaxel bound to albumin nanoparticles. This innovation transformed the treatment landscape for breast, lung and pancreatic cancers and became a multibillion-dollar global therapy. Similarly, he advanced Cynviloq(TM), a novel micellar formulation of paclitaxel that improved delivery while reducing toxicities, further demonstrating his ability to reinvent cancer therapy.

About Oncotelic Therapeutics Inc.

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and codevelops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.

For further information, please visit the company’s website at www.Oncotelic.com. 

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC

NetworkNewsAudio, a service of NetworkNewsWire (NNW), a multifaceted financial news and publishing company powered by IBN (“InvestorBrandNetwork”), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform. Mr. Sharma explains the mechanisms of the drug and also provides insights into the three ongoing clinical trials for each of the potential drug-candidates that could be worth several billion USD each.

During the interview, Sharma explained Lantern Pharma’s core mission and AI-driven approach.

 “We like to think of ourselves as an AI-first company focused on creating cancer medicines. The problem that we’re trying to solve is a massive problem globally: about $250 billion a year is spent on research and development into new cancer medicines, yet it takes 10-to-12 years to go from an idea to an approved drug, and 93% of them fail… To me, this is a perfect problem area for top cancer minds to try to use AI, big data and computational biology to solve. That’s what our team does.”

“We’re maniacally focused on driving AI first. We’ve created computational models from the ground up to focus on different types of cancers and the mechanisms behind them… Imagine being able to aggregate world-class cancer research 24 hours a day and have machine learning models compete to answer complex questions. That’s exactly what we’re doing — using AI to tackle the challenge of creating cancer medicines, with three drug candidates now dosing patients in Japan, Taiwan, and the United States.”

Looking ahead, Sharma highlighted Lantern’s market positioning and outlook.

“The next five to seven years, I see this as an era where many of the most difficult cancers, specifically brain cancers, we’re going to start solving for them. We recently announced a new board member who came from a brain cancer company that just got acquired, and their drug was recently approved… That was one of three brain cancer drugs approved in the last 12-to-14 months (after 17 years without any approvals) signaling a new era in precision neuro-oncology.”

Join IBN’s Stuart Smith and Panna Sharma, President, CEO, and Director of Lantern Pharma, to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Lantern Pharma

Lantern Pharma is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets.

For more information, visit the company’s website at www.LanternPharma.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Panna Sharma, President, CEO, and Director of Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform. Mr. Sharma explains the mechanisms of the drug and also provides insights into the three ongoing clinical trials for each of the potential drug-candidates that could be worth several billion USD each.

During the interview, Sharma explained Lantern Pharma’s core mission and AI-driven approach.

 “We like to think of ourselves as an AI-first company focused on creating cancer medicines. The problem that we’re trying to solve is a massive problem globally: about $250 billion a year is spent on research and development into new cancer medicines, yet it takes 10-to-12 years to go from an idea to an approved drug, and 93% of them fail… To me, this is a perfect problem area for top cancer minds to try to use AI, big data and computational biology to solve. That’s what our team does.”

“We’re maniacally focused on driving AI first. We’ve created computational models from the ground up to focus on different types of cancers and the mechanisms behind them… Imagine being able to aggregate world-class cancer research 24 hours a day and have machine learning models compete to answer complex questions. That’s exactly what we’re doing — using AI to tackle the challenge of creating cancer medicines, with three drug candidates now dosing patients in Japan, Taiwan, and the United States.”

Looking ahead, Sharma highlighted Lantern’s market positioning and outlook.

“The next five to seven years, I see this as an era where many of the most difficult cancers, specifically brain cancers, we’re going to start solving for them. We recently announced a new board member who came from a brain cancer company that just got acquired, and their drug was recently approved… That was one of three brain cancer drugs approved in the last 12-to-14 months (after 17 years without any approvals) signaling a new era in precision neuro-oncology.”

Join IBN’s Stuart Smith and Panna Sharma, President, CEO, and Director of Lantern Pharma, to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Lantern Pharma

Lantern Pharma is an AI company transforming the cost, time, and failure rate of oncology drug discovery and development. Lantern's proprietary AI platform RADR® uses machine learning and multiomic data to solve complex, billion-dollar drug development challenges. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, Lantern has built a pipeline of promising, clinical stage drug candidates, including molecules that target novel cancer mechanisms and targets.

For more information, visit the company’s website at www.LanternPharma.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Robert Thast, CEO of Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers.

To begin the interview, Thast discussed Izotropic’s mission: commercializing its FDA-aligned IzoView Breast CT Imaging System to close critical gaps in early cancer detection.

“Screening is the first line of defense; it’s where lives are saved or not. Current standard of care misses a lot of cancers and is not particularly good at finding aggressive cancers in the early stages. With our Breast CT technology, we can see cancers as small as 2 millimeters. Current standard of care is 11 millimeters average. That’s a big difference—between 12 and 18 months earlier—which could mean the difference between finding it and treating it or having it get past the point of no return.”

Thast also spoke to Izotropic’s intellectual property strategy, competitive outlook, and long-term positioning in the imaging space.

“We have recently announced an AI development and capability that no one else has and may never have. We expect this technology will become increasingly accepted over time, and the majors will have to get involved if they intend to maintain their market share… In terms of protecting our position, we have a portfolio of patents, trade secrets, and products… The majors are certainly going to have the muscle to get in the game — there’s no question about that. I think it’d be a lot less expensive for them to buy something like IzoView, and I expect that’s what will happen as we move forward. We believe we will be a takeover target.”

He then outlined Izotropic’s commercialization strategy, including a phased rollout in Europe and the U.S., supported by clinical validation and significant early demand.

“From a revenue standpoint, our launch will be focused primarily on selling to hospitals, medical facilities, and imaging clinics. Those will be focused on the EU first, followed by the United States… Between the U.S. and Europe, you’re looking at almost 50% of the world market for one of these devices… The FDA study is a clear mandate. If we secure FDA approval, really the world is wide open to us.”

Join IBN’s Carmel Fisher and Robert Thast, CEO of Izotropic Corp., to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Robert Thast, CEO of Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers.

To begin the interview, Thast discussed Izotropic’s mission: commercializing its FDA-aligned IzoView Breast CT Imaging System to close critical gaps in early cancer detection.

“Screening is the first line of defense; it’s where lives are saved or not. Current standard of care misses a lot of cancers and is not particularly good at finding aggressive cancers in the early stages. With our Breast CT technology, we can see cancers as small as 2 millimeters. Current standard of care is 11 millimeters average. That’s a big difference—between 12 and 18 months earlier—which could mean the difference between finding it and treating it or having it get past the point of no return.”

Thast also spoke to Izotropic’s intellectual property strategy, competitive outlook, and long-term positioning in the imaging space.

“We have recently announced an AI development and capability that no one else has and may never have. We expect this technology will become increasingly accepted over time, and the majors will have to get involved if they intend to maintain their market share… In terms of protecting our position, we have a portfolio of patents, trade secrets, and products… The majors are certainly going to have the muscle to get in the game — there’s no question about that. I think it’d be a lot less expensive for them to buy something like IzoView, and I expect that’s what will happen as we move forward. We believe we will be a takeover target.”

He then outlined Izotropic’s commercialization strategy, including a phased rollout in Europe and the U.S., supported by clinical validation and significant early demand.

“From a revenue standpoint, our launch will be focused primarily on selling to hospitals, medical facilities, and imaging clinics. Those will be focused on the EU first, followed by the United States… Between the U.S. and Europe, you’re looking at almost 50% of the world market for one of these devices… The FDA study is a clear mandate. If we secure FDA approval, really the world is wide open to us.”

Join IBN’s Carmel Fisher and Robert Thast, CEO of Izotropic Corp., to learn more about the company’s AI-powered precision oncology platform, pipeline milestones, and vision for transforming cancer treatment.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Izotropic

More information about Izotropic Corporation can be found on its website at izocorp.com and by reviewing its profile on SEDAR at sedarplus.ca.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco explained the devastating nature of glioblastoma and CNS Pharmaceuticals’ commitment to changing the outlook for patients facing this aggressive brain cancer.

“The problem for patients and clinicians in the space is that the cancers take place in the brain behind the blood-brain barrier, which is this very specialized network of cells that prevents otherwise helpful drugs from reaching the site of the cancer.… We believe that is the reason why a cancer like glioblastoma remains one of the two greatest unmet needs in oncology today, the other being pancreatic cancer… There is no cure. Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.”

Reflecting on the company’s response to the berubicin trial, he described how CNS Pharmaceuticals maintained its momentum and repurposed its clinical infrastructure to accelerate the development of a second promising candidate.

“When you have a drug development company, you’ve got to realize that 90% of oncology drug trials fail. Those are the odds that you’re facing… That doesn’t dissuade us at all, because we know these drugs work. We have to prove that; that is our job. So, when we pivoted from our berubicin study to our TPI 287 program, we didn’t miss a beat. We have repurposed all of the work that we did to develop a global clinical network for berubicin over to our TPI program. We really just seamlessly moved forward on that.”

Looking ahead, Climaco outlined the company’s broader ambitions and made the case for its potential in underserved cancer markets.

“When you look at the opportunities in the space that a drug like berubicin or TPI 287 could have, not just in the primary brain cancer space, but in the metastatic space, in triple-negative breast cancer – where 40% of patients have a metastasis to the brain – the multiple and the size of the potential market for these drugs is absolutely enormous… We have demonstrated what I believe is absolutely world-class operational expertise and the ability to bring a trial through to completion on time and on budget. We’ll do it again with TPI, and we hope that we’ll have a positive result and be on our way to a drug approval.

Join IBN’s Stuart Smith and John Climaco, CEO of CNS Pharmaceuticals, to learn more about the company’s vision, clinical programs, and unwavering focus on advancing treatment for brain cancer patients.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the company on X, Facebook, and LinkedIn.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features John Climaco, CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system.

To begin the interview, Climaco explained the devastating nature of glioblastoma and CNS Pharmaceuticals’ commitment to changing the outlook for patients facing this aggressive brain cancer.

“The problem for patients and clinicians in the space is that the cancers take place in the brain behind the blood-brain barrier, which is this very specialized network of cells that prevents otherwise helpful drugs from reaching the site of the cancer.… We believe that is the reason why a cancer like glioblastoma remains one of the two greatest unmet needs in oncology today, the other being pancreatic cancer… There is no cure. Patients have very little hope. Our mission is to change that completely, and we think we have the drugs to do it.”

Reflecting on the company’s response to the berubicin trial, he described how CNS Pharmaceuticals maintained its momentum and repurposed its clinical infrastructure to accelerate the development of a second promising candidate.

“When you have a drug development company, you’ve got to realize that 90% of oncology drug trials fail. Those are the odds that you’re facing… That doesn’t dissuade us at all, because we know these drugs work. We have to prove that; that is our job. So, when we pivoted from our berubicin study to our TPI 287 program, we didn’t miss a beat. We have repurposed all of the work that we did to develop a global clinical network for berubicin over to our TPI program. We really just seamlessly moved forward on that.”

Looking ahead, Climaco outlined the company’s broader ambitions and made the case for its potential in underserved cancer markets.

“When you look at the opportunities in the space that a drug like berubicin or TPI 287 could have, not just in the primary brain cancer space, but in the metastatic space, in triple-negative breast cancer – where 40% of patients have a metastasis to the brain – the multiple and the size of the potential market for these drugs is absolutely enormous… We have demonstrated what I believe is absolutely world-class operational expertise and the ability to bring a trial through to completion on time and on budget. We’ll do it again with TPI, and we hope that we’ll have a positive result and be on our way to a drug approval.

Join IBN’s Stuart Smith and John Climaco, CEO of CNS Pharmaceuticals, to learn more about the company’s vision, clinical programs, and unwavering focus on advancing treatment for brain cancer patients.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.

The company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. The initial clinical efficacy data suggest TPI 287 has the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 also has been tested in over 350 patients in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of a range of diseases or conditions, including recurrent glioblastoma, recurrent neuroblastoma and medulloblastoma, advanced malignancies, advanced unresectable pancreatic cancer, metastatic melanoma, and breast cancer metastatic to the brain. To date TPI 287 appears have both an excellent safety profile and high tolerability among patients.

For more information, please visit www.CNSPharma.com, and connect with the company on X, Facebook, and LinkedIn.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primarily affects older adults. HyBryte has shown strong promise as a first-line treatment option for early-stage CTCL, a market estimated at nearly $1 billion globally, with 70% of that opportunity in the U.S. The therapy has already received orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. Unlike traditional treatments that can take a year or more to show efficacy, HyBryte demonstrated statistically significant results in just six weeks in its initial phase 3 trial. A second confirmatory phase 3 study, FLASH2, is now underway in the U.S. and Europe and is designed to provide further validation of HyBryte’s safety and effectiveness, with top-line results expected in 2026.

HyBryte's safety profile stands out in a treatment space where many existing options carry significant side effects, including DNA damage and long-term carcinogenic risks. The therapy’s use of synthetic hypericin activated by non-carcinogenic visible light — rather than ultraviolet light — offers a safer alternative, especially for older patients. With minimal systemic absorption and strong responses across both patch and plaque lesions, HyBryte has the potential to redefine the standard of care for CTCL. Soligenix's advancements in this rare disease area highlight the growing urgency and opportunity in addressing complex conditions that disproportionately affect aging populations.

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at Soligenix Inc.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

To hear the NetworkNewsAudio version, visit LINK

To read the original editorial, visit LINK

Soligenix Inc. is advancing HyBryte, its late-stage therapy for cutaneous T-cell lymphoma (CTCL), a rare and chronic cancer that primarily affects older adults. HyBryte has shown strong promise as a first-line treatment option for early-stage CTCL, a market estimated at nearly $1 billion globally, with 70% of that opportunity in the U.S. The therapy has already received orphan drug designations in both the U.S. and Europe, as well as FDA Fast Track status. Unlike traditional treatments that can take a year or more to show efficacy, HyBryte demonstrated statistically significant results in just six weeks in its initial phase 3 trial. A second confirmatory phase 3 study, FLASH2, is now underway in the U.S. and Europe and is designed to provide further validation of HyBryte’s safety and effectiveness, with top-line results expected in 2026.

HyBryte's safety profile stands out in a treatment space where many existing options carry significant side effects, including DNA damage and long-term carcinogenic risks. The therapy’s use of synthetic hypericin activated by non-carcinogenic visible light — rather than ultraviolet light — offers a safer alternative, especially for older patients. With minimal systemic absorption and strong responses across both patch and plaque lesions, HyBryte has the potential to redefine the standard of care for CTCL. Soligenix's advancements in this rare disease area highlight the growing urgency and opportunity in addressing complex conditions that disproportionately affect aging populations.

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (“SGX301” or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin (“SGX302”) into psoriasis, the company’s first-in-class innate defense regulator (“IDR”) technology, dusquetide (“SGX942”) for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and (“SGX945”) in Behçet’s disease.

The company’s Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company’s vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix’s vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Defense Threat Reduction Agency (“DTRA”) and the Biomedical Advanced Research and Development Authority (“BARDA”).

For further information, visit the company’s website at Soligenix Inc.

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we're watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public. With an ever-growing distribution network of more than 5,000 key syndication outlets across the nation, NNW cuts through the overload of information in today's markets bringing its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire is where news, content and information converge.

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://NNW.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

To view the full editorial, visit https://nnw.fm/NwefQ

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.

For more information, visit the company’s website at www.CalidiBio.com

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire Austin, Texas www.NetworkNewsWire.com 512.354.7000 Office Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

To view the full editorial, visit https://nnw.fm/NwefQ

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company pioneering the development of targeted therapies that can deliver genetic medicines to sites of disease. The company’s proprietary Redtail platform represents a decade of development and expertise in designing viral vectors that can evade immune detection allowing for systemic delivery and distal sites of disease in oncology and, potentially, other indications. This advanced enveloped technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent gene therapies to metastatic locations.

The lead candidate from the Redtail platform, currently in IND-enabling studies, targets non-small cell lung cancer, ovarian cancer, and other tumor types with high unmet medical need. Additionally, Calidi is developing protected virotherapies, in clinical-stage, for intratumoral and localized administration, focusing on a subset of injectable cancer indications.

For more information, visit the company’s website at www.CalidiBio.com

NOTE TO INVESTORS: The latest news and updates relating to CLDI are available in the company’s newsroom at https://nnw.fm/CLDI

About NetworkNewsAudio

NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.

For more information, visit: www.NetworkNewsAudio.com

About NetworkNewsWire

NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: https://www.NetworkNewsWire.com/Disclaimer

NetworkNewsWire Austin, Texas www.NetworkNewsWire.com 512.354.7000 Office Editor@NetworkNewsWire.com

NetworkNewsWire is powered by IBN

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions.

During the interview, Simeonidis provided an overview of Intelligent Bio Solutions’ core offering and strategic direction.

“We bring a unique technology to the drug screening market,” he explained. “We have a product that detects drugs from the sweat on the top of your fingertips. It’s a whole new way of doing drug screening for people who come to work every single day.”

Simeonidis emphasized the company’s rapid expansion, noting early traction in the U.K. and current deployment across roughly 20 countries. “We’re a non-invasive technology company expanding globally with a lot of growth and revenue,” he said. “We’ve submitted our FDA application, and once we clear that, we expect to be in the U.S. in the second half of the year.”

He described the fingerprint-based test as faster, simpler and more affordable than traditional methods. “You can screen an employee before they actually start work — within 10 minutes,” he noted. “It’s a total game changer.”

Looking ahead, Intelligent Bio Solutions aims to scale through partnerships with U.S. distributors and labs. “They know the customers, they have the install base, and they know how to navigate the market,” Simeonidis said. “Once we get FDA clearance, we’ll increase our marketing campaigns. Once people know about the product, the adoption rate is very fast.”

Join IBN’s Carmel Fisher and Harry Simeonidis, President and CEO of Intelligent Bio Solutions, to learn more about the company’s entry into the U.S. market, plans for FDA clearance and how its fingerprint-based drug screening platform is reshaping workplace safety.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under 10 minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit the company’s website at www.IBS.inc

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Harry Simeonidis, CEO of Intelligent Bio Solutions Inc. (NASDAQ: INBS), a medical technology company delivering intelligent, rapid, non-invasive testing solutions.

During the interview, Simeonidis provided an overview of Intelligent Bio Solutions’ core offering and strategic direction.

“We bring a unique technology to the drug screening market,” he explained. “We have a product that detects drugs from the sweat on the top of your fingertips. It’s a whole new way of doing drug screening for people who come to work every single day.”

Simeonidis emphasized the company’s rapid expansion, noting early traction in the U.K. and current deployment across roughly 20 countries. “We’re a non-invasive technology company expanding globally with a lot of growth and revenue,” he said. “We’ve submitted our FDA application, and once we clear that, we expect to be in the U.S. in the second half of the year.”

He described the fingerprint-based test as faster, simpler and more affordable than traditional methods. “You can screen an employee before they actually start work — within 10 minutes,” he noted. “It’s a total game changer.”

Looking ahead, Intelligent Bio Solutions aims to scale through partnerships with U.S. distributors and labs. “They know the customers, they have the install base, and they know how to navigate the market,” Simeonidis said. “Once we get FDA clearance, we’ll increase our marketing campaigns. Once people know about the product, the adoption rate is very fast.”

Join IBN’s Carmel Fisher and Harry Simeonidis, President and CEO of Intelligent Bio Solutions, to learn more about the company’s entry into the U.S. market, plans for FDA clearance and how its fingerprint-based drug screening platform is reshaping workplace safety.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc. is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The company believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under 10 minutes, this technology would be a valuable tool for employers in safety-critical industries. The company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, drug treatment organizations, and coroners.

For more information, visit the company’s website at www.IBS.inc

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

AUSTIN, Texas, May 27, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ: NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products.

During the interview, Sheridan provided an introduction to Nutriband’s business model.

“We’re a pharmaceutical company specifically focused on transdermal technology… Our core focus is on a segment of the industry that has been overlooked and underrepresented for quite some time now – adequate pain management in the transdermal space. We’re all familiar and aware of the opiate scandals over the last 10 years and the fallout from that. It resulted in a very negative opiate stigma surrounding all of pain management, but the real fallout was actually a lack of adequate care for pain patients. We’re tackling this head-on with our AVERSA™ technology.”

“It is a platform tech that we’ve developed internally that can be applied to any pain patch medication with the goal of making them very difficult to abuse. Because of that, we’re also making these medications accessible to patients who have had their access cut in recent years… Our first application for AVERSA is a fentanyl patch. Fentanyl is a scary word in a lot of people’s vocabulary, but, when used correctly, fentanyl is a very effective pain medication… Unfortunately, because of the fallout from the opiate scandals we’ve seen in recent years, these types of products have been faced with a major reluctance when it comes to prescribers, insurance companies, and payers. Nobody wants to deal with the liability issues associated with these products.”

“You saw companies actually getting out of the space and moving on, but the people who felt the fallout from this were actually the pain patient themselves. Prescription rates are down an astronomical number since their height in 2016, when fentanyl patches, for example, were about a $4 billion a year market. They're under $1 billion a year now in terms of market size, but the patient population requiring access to these medications has not reduced by 75%. We're looking at a massive disconnect between adequate management and adequate care for patients on prescription rates. That's something that we'll tackle head-on with our AVERSA technology.”

Join IBN’s Carmel Fisher and Gareth Sheridan, Co-Founder and CEO of Nutriband, to learn more about the company’s development pipeline, as well as the unique ways AVERSA helps address abuse of pain medication.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

For more information, visit the company’s website at www.Nutriband.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ: NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products.

During the interview, Sheridan provided an introduction to Nutriband’s business model.

“We’re a pharmaceutical company specifically focused on transdermal technology… Our core focus is on a segment of the industry that has been overlooked and underrepresented for quite some time now – adequate pain management in the transdermal space. We’re all familiar and aware of the opiate scandals over the last 10 years and the fallout from that. It resulted in a very negative opiate stigma surrounding all of pain management, but the real fallout was actually a lack of adequate care for pain patients. We’re tackling this head-on with our AVERSA™ technology.”

“It is a platform tech that we’ve developed internally that can be applied to any pain patch medication with the goal of making them very difficult to abuse. Because of that, we’re also making these medications accessible to patients who have had their access cut in recent years… Our first application for AVERSA is a fentanyl patch. Fentanyl is a scary word in a lot of people’s vocabulary, but, when used correctly, fentanyl is a very effective pain medication… Unfortunately, because of the fallout from the opiate scandals we’ve seen in recent years, these types of products have been faced with a major reluctance when it comes to prescribers, insurance companies, and payers. Nobody wants to deal with the liability issues associated with these products.”

“You saw companies actually getting out of the space and moving on, but the people who felt the fallout from this were actually the pain patient themselves. Prescription rates are down an astronomical number since their height in 2016, when fentanyl patches, for example, were about a $4 billion a year market. They're under $1 billion a year now in terms of market size, but the patient population requiring access to these medications has not reduced by 75%. We're looking at a massive disconnect between adequate management and adequate care for patients on prescription rates. That's something that we'll tackle head-on with our AVERSA technology.”

Join IBN’s Carmel Fisher and Gareth Sheridan, Co-Founder and CEO of Nutriband, to learn more about the company’s development pipeline, as well as the unique ways AVERSA helps address abuse of pain medication.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Nutriband Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

For more information, visit the company’s website at www.Nutriband.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs.

During the interview, Schaber provided an introduction to Soligenix’s business model.

“I think what makes Soligenix unique is that we have two areas of focus. Our Specialized BioTherapeutics segment is focused on small molecules in oncology, and inflammation. Through a separate Public Health Solutions segment of our business that’s been funded entirely by the U.S. government – in excess of $60 million in non-dilutive funding over the years – we focus predominantly on heat-stable vaccines for emerging infectious diseases and biothreats. Through these segments, we’ve been able to build out a more robust pipeline than you would typically see for a company our size, with multiple ‘shots on goal’ to mitigate risk.”

Schaber next discussed how Soligenix is adapting to current uncertainties surrounding federal research funding and priorities.

“We focus on what we can control – our primary programs that we’re actively enrolling. We have three clinical studies, including one confirmatory Phase 3. We’re focusing our time, resources, and effort there, and if additional non-dilutive government funding comes that can support our public health business segment, then we will continue to advance that. In times like this, you need to focus in on those things that you can get across the finish line as quickly as possible.”

“Beyond the capital that we’ve raised to support the clinical studies we’re pursuing, we are always submitting government grant contracts to get additional funding. That remains a piece of our business that we really focus on. Another thing that we’re really focused on in the near term is business development opportunities and looking at all strategic options. As you would imagine with a late-stage pipeline like ours and active programs – especially a confirmatory study in a rare cancer – there is interest. We are in a number of discussions that could range anywhere from regional partnership to M&A.”

Join IBN’s Carmel Fisher and Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix, to learn more about the company’s HyBryte™ clinical programs, as well as the key milestones on Soligenix’s radar for the balance of 2025.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

For more information, visit the company’s website at www.Soligenix.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs.

During the interview, Schaber provided an introduction to Soligenix’s business model.

“I think what makes Soligenix unique is that we have two areas of focus. Our Specialized BioTherapeutics segment is focused on small molecules in oncology, and inflammation. Through a separate Public Health Solutions segment of our business that’s been funded entirely by the U.S. government – in excess of $60 million in non-dilutive funding over the years – we focus predominantly on heat-stable vaccines for emerging infectious diseases and biothreats. Through these segments, we’ve been able to build out a more robust pipeline than you would typically see for a company our size, with multiple ‘shots on goal’ to mitigate risk.”

Schaber next discussed how Soligenix is adapting to current uncertainties surrounding federal research funding and priorities.

“We focus on what we can control – our primary programs that we’re actively enrolling. We have three clinical studies, including one confirmatory Phase 3. We’re focusing our time, resources, and effort there, and if additional non-dilutive government funding comes that can support our public health business segment, then we will continue to advance that. In times like this, you need to focus in on those things that you can get across the finish line as quickly as possible.”

“Beyond the capital that we’ve raised to support the clinical studies we’re pursuing, we are always submitting government grant contracts to get additional funding. That remains a piece of our business that we really focus on. Another thing that we’re really focused on in the near term is business development opportunities and looking at all strategic options. As you would imagine with a late-stage pipeline like ours and active programs – especially a confirmatory study in a rare cancer – there is interest. We are in a number of discussions that could range anywhere from regional partnership to M&A.”

Join IBN’s Carmel Fisher and Dr. Christopher Schaber, Chairman, President, and CEO of Soligenix, to learn more about the company’s HyBryte™ clinical programs, as well as the key milestones on Soligenix’s radar for the balance of 2025.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Soligenix Inc.

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte™ (“SGX301” or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.

For more information, visit the company’s website at www.Soligenix.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Shane Speirs, CEO of Adageis, a healthcare technology company dedicated to revolutionizing patient care through innovative solutions.

During the interview, Speirs provided an introduction to Adageis’ business model.

“Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Speirs explained. “On the healthcare delivery side, it's also tough. Classically, there have been different reimbursement methods for healthcare services in the United States, but many agree the future is value-based care.”

“What Adageis does is provide a simple solution to healthcare organizations – ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with… Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

“One of the major challenges in the marketplace is the sheer complexity – there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance.”

Join IBN’s Carmel Fisher and Shane Speirs, CEO of Adageis, to explore the company’s sustained efforts to maintain seamless interoperability while implementing cutting-edge, AI-driven analytics.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector.

For more information, visit the company’s website at www.Adageis.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Shane Speirs, CEO of Adageis, a healthcare technology company dedicated to revolutionizing patient care through innovative solutions.

During the interview, Speirs provided an introduction to Adageis’ business model.

“Healthcare is a complicated place, and navigating the system is extremely difficult for patients,” Speirs explained. “On the healthcare delivery side, it's also tough. Classically, there have been different reimbursement methods for healthcare services in the United States, but many agree the future is value-based care.”

“What Adageis does is provide a simple solution to healthcare organizations – ranging from large, multi-state, multi-specialty healthcare groups to independent practices across the country. We offer a solution that meets everyone's needs, helping providers and organizations drive revenue by delivering high-quality care, which everyone can align with… Much of the value in value-based care comes from providing proper documentation to patients and being proactive with screenings. We provide an easy solution for practices to indicate the metrics needed for patients, to provide high-quality care while maximizing incentive dollars.”

“One of the major challenges in the marketplace is the sheer complexity – there are over 100 insurance companies with more than 1,000 plans in the Phoenix area alone. Each has different measures and unique documentation requirements… Adageis has a solution that integrates with nearly 100 electronic health record systems, overlaying existing platforms to provide easy-to-read measures tailored to each patient’s insurance.”

Join IBN’s Carmel Fisher and Shane Speirs, CEO of Adageis, to explore the company’s sustained efforts to maintain seamless interoperability while implementing cutting-edge, AI-driven analytics.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Adageis

Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector.

For more information, visit the company’s website at www.Adageis.com

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Austin, Texas www.InvestorBrandNetwork.com 512.354.7000 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.

“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”

“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”

“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”

Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

The BioMedWire Podcast showcases fast-paced interviews with industry experts pioneering pharmaceutical and biotech advancements. The latest episode features Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD).

In this episode, Dr. Maccecchini discusses the company’s recent meetings with the U.S. Food and Drug Administration (FDA), which resulted in clearance to initiate pivotal Phase 3 studies of buntanetap in early-stage AD patients.

“To date, we have conducted four small studies in Alzheimer’s, and now the FDA has granted us clearance to do the very last study, which is really a confirmation of the study we just completed,” she explains. “Once we have that confirmation, we’ll be able to submit a request for market approval.”

“We are so excited about this data, because buntanetap is good in both Alzheimer’s and Parkinson’s. The reason that we believe it works in a number of neurodegenerative diseases is that it attacks more than one neurotoxic protein. What pharma has done to date is attack mostly amyloid-beta plaques. If you attack plaques, you get a small response. However, if you attack more than one toxic protein, and in the brain of an Alzheimer’s patient there are at least four toxic proteins, you have a better outcome.”

“Our limited data in the three-month study we just did shows that our drug has better efficacy than the existing drugs on the market, at least in the short term. We have differentiated ourselves from other approaches with our mechanism of action for over 10 years, but the question is, does it improve cognition while being different? The exciting thing is that the FDA believes it's worth reproducing the data we have to prove that, in fact, it works. The FDA always wants you to have two studies, and this new pivotal Phase 3 studies will serve as a confirmation of the previous findings.”

Join IBN’s Carmel Fisher and Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, to learn more about the company’s strategy to move rapidly toward a potential New Drug Application (NDA) filing following commencement of its upcoming Phase 3 study.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

About Annovis Bio Inc.

Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.

About IBN

IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

IBN Los Angeles, California www.InvestorBrandNetwork.com 310.299.1717 Office Editor@InvestorBrandNetwork.com

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.

“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”

“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”

“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”

Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

To begin the interview, Climaco discussed CNS Pharmaceuticals’ business model, including the company’s recent announcement of an exclusive in-license agreement to expand its development pipeline.

“We are an oncology drug development company. Specifically, our space is neuro-oncology – cancers of the brain and the central nervous system. Traditionally, these are some of the most difficult and deadly cancers,” he said. “They are very challenging to treat, because they lie beyond the blood-brain barrier, which is this very specialized network of cells that protects the most important organ in the body. It's very hard to get drugs and treatments to the brain when you have tumors growing in it, so that is really what we specialize in.”

“We have a very exciting compound called Berubicin. It's a first-in-class drug that penetrates the blood-brain barrier and treats brain cancer. This is in a late stage, designed to be pivotal trial, with over 250 patients in the United States and Europe currently enrolled. It'll be reading top-line data in the first half of next year, so we're very excited about that. We've been working on Berubicin since the company's inception back in 2017.”

“Our recent news is equally exciting. After many years of searching and diligence and evaluating over 200 different compounds for potential in-license, we settled on an amazing drug called TPI-287, which is a novel abeotaxane of the taxane family. This is also a unique blood-brain barrier penetrant drug that was specifically designed to treat these very difficult brain cancers, such as glioblastoma. This drug has already been used in 350 patients in a series of phase one studies. We are just getting started on planning what will be another designed to be pivotal study for this very exciting drug.”

Join IBN’s Carmel Fisher and John Climaco, CEO of CNS Pharmaceuticals Inc., to learn more about what sets Berubicin, as well as the company’s new TPI-287 candidate, apart from anything else in development for glioblastoma.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 18 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine

To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”

To begin the interview, Etherington discussed Clene’s mission, including its novel approach to the treatment of diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

“Clene Inc. is focused entirely on improving mitochondrial health and protecting neuron function. This is a very important thing we can do to treat neurodegenerative diseases such as ALS, MS and Parkinson's,” he said. “This is particularly topical today, because the World Health Organization is predicting that neurodegenerative diseases will become the second-most prevalent cause of death within the next two decades. We're pioneering a very unique approach: the use of an oral suspension that patients can drink to treat the deficits that they might have if afflicted with one of these devastating neurodegenerative diseases.”

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

Broadcasting live from AAIC 2024, Dr. Maccecchini delves into the detailed findings from Annovis Bio’s recent Phase 2/3 Alzheimer’s study of its lead drug candidate, buntanetap. During the interview, she provides insights into how the scientific community is reacting to the promising data and what it could mean for the future of neurodegenerative disease treatment. Additionally, Dr. Maccecchini discusses Annovis Bio’s strategic plans moving forward, including potential regulatory milestones and upcoming clinical trials that aim to further validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases.

“Our Phase 2/3 data indicates that buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients,” said Dr. Maccecchini during the interview. “Being able to share these findings live from AAIC, one of the most prestigious events in Alzheimer’s research, underscores the importance of our work and the promise it holds for patients.”

Join IBN’s Stuart Smith and Dr. Maria Maccecchini to learn more about Annovis Bio’s recent achievements, the next steps for buntanetap, and the company’s future goals.

To begin the interview, Reichman discussed Scinai Immunotherapeutics’ business model.

“Scinai is developing its own innovative pipeline of biological therapeutic products based on a unique technology of VHH single domain antibodies originating from alpacas,” he said. “The antibodies are licensed from the Max Planck Institute and the University Medical Centre Göttingen, both in Germany. The two principal investigators with whom who we work are Professor Dirk Görlich and Professor Matthias Dobbelstein.”

Join IBN’s Carmel Fisher and Amir Reichman, CEO of Scinai Immunotherapeutics, to learn more about the company’s recent milestones.

To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com

To watch the latest episode, visit https://ccw.fm/541vg

To watch the latest episode, visit https://ccw.fm/IZnkH

To watch the latest episode, visit https://ccw.fm/3FeGF

BroadcastMay 14, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.

The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.

Broadcast Apr 23, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.

The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.

To watch the latest episode, visit https://ccw.fm/wUVUk

To watch the latest episode, visit https://ccw.fm/n614x

To watch the latest episode, visit https://ccw.fm/Qy0En

Broadcast March 26, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.

The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.

Broadcast Mar 23, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.

The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.

Broadcast Mar 16, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.

The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.

To watch the latest episode, visit https://ccw.fm/G0V7Z

To watch the latest episode, visit https://ccw.fm/NxDKi

Broadcast Feb 18, 2021. The latest news from around the cryptocurrency/blockchain space with Crypto Currency Wire's Communications Director, Jonathan Keim.

The Wild West Crypto Show is the brainchild of Drew Taylor. Drew created this platform as a tool to inform people about cryptocurrency so that they can make educated decisions about investing in this emerging market. Together with his co-host Brent Bates and with the help of industry experts, Drew and the Wild West Crypto Shows aims for providing valuable information for anyone interested in cryptocurrency, all while debunking myths and misinformation often spread about the movement.

To watch the latest episode, visit https://ccw.fm/FvFHA

To watch the latest episode, visit https://ccw.fm/NzmPY

To watch the latest episode, visit https://ccw.fm/3SX3b

To watch the latest episode, visit https://ccw.fm/KHZGb

He kicked off his Weekly News Update with a report that: US Fed economists are exploring the ‘intrinsic’ value drivers of CBDCs (https://ccw.fm/LiKvH). CBDCs are digital currencies issued by a central bank. They appear to differ from regular fiat currencies by being directly issued to consumers rather than through the banking system. The Fed is considering the possibility of issuing such a CBDC and has initiated a study to explore “the potential impact of a digital dollar on commercial banking and monetary policy.”

Other countries, notably China, have already launched digital currency programs. In October, the People’s Bank of China distributed 200 digital yuan ($29.75) each to 50,000 randomly selected consumers with online digital wallets, in a pilot project to test the waters. Central banks around the world are considering CBDCs, concerned that growing use of cryptocurrencies may reduce their ability to manage local monetary systems and economies, to detrimental effect.

In other news:  Fund execs offer $1M bets that Bitcoin’s S2F model won’t come true (https://ccw.fm/3Wvo6). Two executives at crypto hedge funds are prepared to place bets against the Bitcoin stock-to-flow model, developed by Dutch investor Plan B, which predicts a price of $100,000-$288,000 before December 2021. Eric Wall, chief investment officer of crypto hedge fund Arcane Assets, is willing to stake $1 million that the prediction will fail. He’s so sure, he’s extended the wager period to 2025. And Ari Paul, CIO at BlockTower Capital, says he would give 3:1 odds on the same bet against the S2F model, which means he’ll gain $1 million if he wins and have to pay out $3 million if he loses.

Finally, InvestorBrandNetwork (“IBN”) Announces Latest Episode of Stock2Me Podcast Featuring Bestselling Author John Truman Wolfe (https://ccw.fm/38rC3). The Stock2Me Podcast, hosted by Stuart Smith, is an initiative of InvestorBrandNetwork (“IBN”), a multifaceted communications organization that connects public companies to the investment community. The podcast is designed to provide specialized content distribution via widespread syndication channels. The current episode features Strategic Financial Intelligence editor John Truman Wolfe sharing his perspectives on the continuing evolution and adoption of decentralized currencies, the impending rise of centralized digital currencies and the long-term effects of recent economic policy decisions in the U.S.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit https://ccw.fm/p1DyD

“I was just amazed at all the progress that’s being made. … There’s no doubt that this is the year that will be a key landmark in the history of digital finance,” Keim said.

Keim noted that 86 percent of financial institutions that took part in a Europe-wide survey are implementing or assessing services that use DeFi.

“But the really amazing thing is that 31 percent of those companies are reporting an enterprise-wide rollout or have at least deployed an actual use case of DeFi already,” Keim said. “And quite honestly I don’t think I’ve ever seen banks move forward so quickly on anything. I remember hearing DeFi in just the last 12 months and here a third of these companies are already on the train.”

Keim also noted that Singapore’s largest bank plans to launch its own crypto exchange, establishing a relatively easy to access crypto on-ramp for people who bank in that country. Taylor compared it to JPMorgan Chase’s announcement it is going to develop its own coin.

“It’ll be interesting to see how all this evolves and where all these big financial institutions fit into this,” Taylor said.

Regarding PayPal’s plans to potentially launch its own crypto in the next six to 12 months, Keim said the CSO for digital asset manager CoinShares is pointing out PayPal’s immense base of more than 300 million active users and the fact that PayPal has left the Libra Association, which it joined last year to help govern Facebook’s Libra digital currency project.

PayPal announced in October that it has partnered with cryptocurrency company Paxos and that it plans to let its U.S. users buy, hold and sell cryptocurrencies and eventually to use their crypto assets to fund PayPal purchases, but it has not stated it intends to launch its own coin (https://ccw.fm/KLquz).

“I can’t help but think that (CoinShare’s CSO) knows more than we do and he just wants to be one of the first to call it,” Keim said.

“(PayPal has) already got a fairly seamless way to put it in and take it out of your bank account,” Bates said. “I remember the very first show we talked about how difficult it was to get money from a bank into a crypto account. It came the other way real quick; it’ll only take a day or two to get out of your crypto account and get into the bank but it took a week to 10 days to get from the bank to there. PayPal’s already got that relationship, already has the portal of getting in and out.”

The Wild West Crypto Show podcast appears online and in multiple markets across the country. Bates’ and Taylor’s purpose is to educate people about alt-currencies “so that they’re not afraid of it.” To view the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring recent news from around the world, visit https://ccw.fm/h6pks.

When Cointelegraph reported that U.S. Currency Comptroller Brian Brooks stated that decentralized finance movements will spawn “inevitable” change and will render many of the services banks provide obsolete, “just as email disrupted the postal service,” Keim called it a sign that “everybody is waking up” to a fact that he and the show’s hosts have previously discussed many times.

“It’s just exciting when you hear people like Brian Brooks say these kinds of things. We’re seeing so much movement in this past year. It’s really insane. And not just here in the U.S. but abroad as well,” Keim added.

Keim also noted that the chairman of the U.S. Federal Reserve has said its financial institutions aren’t in a hurry to introduce central bank digital currency, which prompted Morgan Creek Digital co-founder Anthony Pompliano to argue that time is of the essence and if it doesn’t act “the U.S. is going to fall really far behind China because it all comes down to accessibility.”

“In our small town, we have a bank and a chicken place on every corner and a convenience store across the street. We’ve got plenty of all that sort of stuff,” Bates quipped. “The U.S. getting involved in this is going to help all those unbanked people and is going to help all these other economies by being able to provide liquidity and everything that the U.S. dollar and digital dollar could bring.”

Bates expressed excitement at news that crypto gaming pioneer Cloudbet is adding Pax Gold coin to its platform to make betting with gold backing possible in a first for the gaming world.

“You can’t carry all your gold with you. It becomes heavy and kind of hard to lug around,” Bates said. “You take that little thumb drive around with you, it could have a billion dollars or it could have 59 cents and everything in between. It’s so much more pragmatic for it to be digitized and to carry around a piece of it.”

Keim said what he finds so interesting is that there are so many alternatives to the dollar “springing up all over the place” as means for currency transactions.

“This world-first accomplishment is only feasible because a gold-backed crypto is easily divisible and easier to exchange,” he said.

The Wild West Crypto Show podcast appears online and in multiple markets across the country. Bates’ and Taylor’s purpose is to educate people about alt-currencies “so that they’re not afraid of it.”

To view the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring recent news from around the world, visit https://ccw.fm/YLUvo.

Regarding a CoinDesk report about Stone Ridge Asset Management’s more than $100 million investment in bitcoin as part of a billion-dollar spin-off, echoing business intelligence company MicroStrategy in terming bitcoin a “primary treasury reserve asset,” Keim said he thinks the term is going to catch on.

“Institutional asset managers like this one and others are really seeing bitcoin in a new light. They’re even coming up with new terms, like this one,” Keim said. “So, it’s helping everyone understand what bitcoin is and it’s quite frankly getting contagious at this point.”

Taylor also noted a Decrypt report on Fidelity Digital Assets’ turnaround in regard to its views on bitcoin, shedding its adverse opinions three years ago to tout bitcoin as a unique vehicle among investment assets.

“I really think Fidelity nailed it in their research,” Keim said. “Ultimately the research points out how bitcoin is uniquely decoupled from other asset classes. . . . In conclusion, the report said, ‘Bitcoin is a unique, investable asset with compelling differences relative to both traditional asset classes as well as conventional alternative investments.’ And then, just rounding off the sentence, they said, ‘That could make it a beneficial addition to portfolios.’ So they’re kind of hinting, you know, this might be something you want to take a look at.”

The Wild West Crypto Show appears on TV in multiple markets across the country as well as online as a humorous and educational forum for providing information with the intent of reducing some of the consumer wariness about alt-currency. To view the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring recent news from around the world, visit https://www.ccw.fm/Tldyi

“The fact that 70% of the 35,000 respondents are now spending crypto, and not just HODLing it, means that it’s really achieved currency status,” Keim said.

“To all these restaurants we’ve been telling, ‘You can give yourself a raise if you just start accepting cryptocurrency and you’re not paying’ … people don’t realize that because the credit card fees are 2 to 3%, if your profit margin’s 12%, 25% of it’s getting eaten up by processing fees,” Taylor added.

Keim also discussed the logic of using cryptocurrencies in IRAs to gain tax-free benefits.

“For those who were burnt by big gains reported in 2017 that later evaporated in the 2018 tax year, or they were just overwhelmed by the tracking requirements, it really makes total sense why IRAs are especially appealing to crypto traders,” he said. “An economist that advises iTrustCapital believes IRAs will be a key part of the $1.5 trillion of capital expected to move into the digital asset space within the next five to seven years.”

Bates noted that using cryptocurrencies in IRAs takes off some of the pressure that comes from watching markets rise and fall, because the investor is instead using a long-term perspective for a sector that is continuing to grow over time.

“The other problem that it solves . . . there are now insured funds and everything else, so that the people that have been afraid of losing all this in the crypto market because it’s just a big black hole, you do have these insured funds, U.S. funds . . . where you can take self-directed IRAs and other things and put it in,” Taylor added. “If you believe in crypto the way . . . we do, they are going to be an appreciating asset that may outperform many other things.”

And Keim noted that Bitcoin payment gateway Abra’s CEO was recently quoted as saying he’s “never been this excited about the potential of Bitcoin for a significant price appreciation in the short term,” looking at the possibility of “50,000 and beyond,” providing an insider’s perspective on growing adoption.

The Wild West Crypto Show is a podcast that appears on TV in multiple markets across the country as well as online, “educating people about cryptocurrency so that they’re not afraid of it.” To view the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring recent news from around the world, visit www.ccw.fm/KjKb9.

The Cambridge Report numbers indicate that the mining business is alive and well, although it has suffered contraction over the past year, with many outfits targeting more than one cryptocurrency.  The report notes that approximately 89% of crypto mining respondents are mining Bitcoin (“BTC”), with 35% mining ether (“ETH”), and with bitcoin cash at 30%.

Next on Keim’s Weekly News Update was the headline: “Payments Platform Wirex Reaches Target for First Crowdfund in 1 and a Half Hours” (https://ccw.fm/mLRBh). Capitalizing on increasing awareness of its platform, British digital payments processor Wirex was able to raise £1 million, as planned, in record time. The company also exceeded the fundraising target by taking in £1.6 million, an amount likely to increase, since its crowd-funding campaign seems set to remain open for some time.

Wirex is the first cryptocurrency platform to be granted a MasterCard principal membership. The processor plans to issue a multicurrency Wirex Card, which will be supported by MasterCard and linked to 19 crypto and fiat currency accounts in the Wirex app. Wirex is regulated by the U.K.’s Financial Conduct Authority, with a license to issue crypto cards in Europe.

Last but most definitely not least, comes a warning from U.S. Financial Crimes Enforcement Network (FinCEN) director Kenneth Blanco: “FinCEN Director Warns Banks about Cryptocurrency Risk Exposure” (https://ccw.fm/1Iu9R). At a recent anti-money-laundering (“AML”) conference, the FinCEN chief reminded banks about their obligations to institute effective AML policies, particularly with regard to cryptocurrency transactions.

In 2019, crypto analytics firm CipherTrace Labs found that eight of the ten major U.S. retail banks had done business with illicit crypto money service businesses (“MSBs”). Many MSBs provide cryptocurrencies to customers in exchange for cash, a service which while not illegal per se, requires the MSB to be regulated. Individuals too have fallen foul of the law. Again, buying or selling a cryptocurrency is not in itself illegal but doing so “as a business” is. Conducting more than a handful of transactions can get someone accused of operating an unlicensed money-transmitting business, an offense that carries up to five years behind bars.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit https://ccw.fm/weke4.

The second headline on Keim’s list stated this: Cryptocurrencies Are Primary Investments for Many, Finds New Huobi Survey (https://ccw.fm/KIx6D). A Huobi (pronounced HO-BE) study has revealed that in “emerging markets across Europe, Asia, Africa, and South America,” many new consumers of financial products are purchasing “digital assets like Bitcoin (‘BTC’) and ether (‘ETH’),” instead of more established ones, such as stocks, bonds and mutual funds.

Digital assets appear to be a greater attraction for the less-experienced consumer, which may contribute to greater volatility in the cryptocurrency markets. Huobi is a cryptocurrency exchange with headquarters in Singapore. The name has been translated variously as “hot coin” or “popular coin.”

Finally, Keim’s last headline: Are We Dumb? Financial Illiterates ‘Twice as Likely to Own Crypto.’ This news seemed to validate the results of the Huobi survey (https://ccw.fm/xwZwg). An investigation by Canada’s central bank indicates that “financial literacy is positively associated with the awareness of cryptocurrencies but negatively associated with ownership.” The Bank of Canada’s 2019 Cash Alternative Survey reveals that while many Canadians are familiar with both established and crypto financial products, very few of these financially literate consumers “actually hold any crypto assets.”

Crypto assets, it seems, are purchased mainly by the less informed as financial neophytes, lured by the high expected returns, fail to take account of the risks. Not only are cryptocurrency markets notoriously volatile but they appear to operate independently of economic conditions in the real world, making it difficult if not impossible to identify their intrinsic characteristics, which is why the Wild West Crypto Show advises: never risk more than you would risk on a roll of dice in Vegas.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit https://ccw.fm/xWxXJ.

Back in 2013, Michael Saylor, CEO of Nasdaq-listed data analytics firm MicroStrategy, tweeted, “Bitcoin days are numbered. It seems like just a matter of time before it suffers the same fate as online gambling.” Now, seven years later, the MicroStrategy chief appears to have had an epiphany. His company recently purchased a quarter of a billion dollars’ worth of Bitcoin, announcing the transaction with the declaration that Bitcoin “as the world’s most widely adopted cryptocurrency, is a dependable store of value and an attractive investment asset with more long-term appreciation potential than holding cash.”

Next up Keim shared this news: “Thai Central Bank’s New Blockchain-Enabled Bond Infrastructure Passes Test with $1.6B Bond Sale” (https://ccw.fm/HEsIA). Monetary authorities in Thailand have managed to sell government savings bonds to the tune of 50 billion baht (approximately $1.6 billion) in just one week. A release issued by the Bank of Thailand said the blockchain-enabled platform would “enhance investors’ buying experience, improve operational efficiency and reduce overall cost.” Thailand has enthusiastically embraced blockchain technologies and applications, including cryptocurrencies. To date, Thai regulators have approved 13 crypto businesses, including cryptocurrency exchanges, brokers and dealers, to legally operate in the country.

In Keim’s last report — no one can refuse China’s digital currency, says central bank exec — authorities in the People’s Republic have stamped the soon-to-be-issued digital yuan with their imprimatur (https://ccw.fm/XzAiN). In a recent press release, the deputy governor of China’s central bank said the digital currency would be on par with existing fiat money. China’s digital currency — digital currency electronic payment, or DCEP — has yet to be launched, but trials on its use have been underway for some time, according to a Bloomberg report (https://ccw.fm/JKVID). There is speculation that its debut may coincide with the 2022 Winter Olympics, set for Feb. 4–20, 2022.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit https://ccw.fm/a1w8n.

With its adoption of the Nasdaq technology, Bitstamp will be able to manage the full range of trading functions — from price formation to order matching — for a wide range of assets. Nasdaq makes it technology available to exchanges and traders through its marketplace technology unit.

In other news, the major card networks are upping their cryptocurrency game: MasterCard launches digital currency kit for central banks (https://ccw.fm/QTDYx). MasterCard has launched a blockchain-based platform that it hopes will win influential new customers, namely central banks.

The Central Bank Digital Currencies Testing Platform, as it is known, will offer a way to experiment with the issue of digital currencies, perhaps ushering in a wave of sweeping change to current payment systems. Although cryptocurrencies such as Bitcoin are digital currencies, central bank-issued digital currencies would differ in that they would be regulated by a government authority and require proof of identity to use, just like fiat.

Finally, a headline that’s sure to grab attention: Buffett dumps Wells Fargo, amplifying bull case for gold and Bitcoin (https://ccw.fm/qf1fH). Famed investor Warren Buffett has sold 100 million shares, a large part of his stake in Wells Fargo, after the bank posted a loss of $2.4 billion in the second quarter, its first quarterly loss since the financial crisis of 2008. The drastic decline in earnings stems from the unusually high loan loss provisions made, as the coronavirus pandemic raises default risks for customers.

The report raises moot points. How exactly selling shares in America’s fourth-largest bank benefits Bitcoin is not clear, nor is how the share sale amplifies the “bull case for gold and Bitcoin.” Nevertheless, in some quarters, the cryptocurrency is considered to be a safe haven, despite having a volatility about twice that of gold (https://ccw.fm/HcifU).

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit https://ccw.fm/kVEgU.

Despite its size — population of 30,000 — the small town is home to cryptocurrency exchange Shapeshift, as well as the Ethereum Foundation. Opening its arms to the latter has proven to be a game changer. The presence of the Ethereum Foundation has precipitated an entire ecosystem of service providers and developers within the community. With this latest pronouncement, which allows companies and private individuals to pay taxes up to an amount of 100,000 Swiss francs ($109,670), the canton maintains its place as a leader in crypto regulation.

In other news, social content publishing platform The Capital claims that Bitcoin is now the sixth-largest world currency (https://ccw.fm/YpEMB). The Capital report states that “at its current market cap, Bitcoin has a money supply worth more than 170 different fiat currencies,” which is a good indication that contrasting the money supply of various world currencies to Bitcoin valuation may be a bit of an apples-to-oranges comparison.

Despite being dubbed a currency, Bitcoin seems to lack three essential characteristics — medium of exchange, store of value and unit of account — that money must have. Many businesses and individuals will transact in Bitcoin, but the currency is still not widely enough accepted to be a medium of exchange. Moreover, its price fluctuations make it ill-suited to qualify as a store of value or a unit of exchange.

Keim’s final headline, CFTC Greenlights LedgerX Request to Move Beyond Digital Currency Products, shows regulators are warming to the idea of digital assets (https://ccw.fm/QgqEK). The CFTC has announced its approval of the LedgerX application to offer fully collateralized futures and options products in addition to the digital asset swaps it already provides. The CFTC order effectively removes the distinction between derivatives on digital assets and those with more established bases, such as commodities, stocks, bonds, interest rates and currencies. Now investors should find it a tad easier to cut risk as they search for returns in the current pandemic-plagued environment.

To view the most recent episode of “The Wild West Crypto Show,” now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit https://ccw.fm/PlMwA

If anyone had doubts that cryptocurrencies are now totally mainstream, they can lay that uncertainty to rest. America’s largest 401(k) provider, Fidelity, plans to start a new fund entirely devoted to Bitcoin. Called the Wise Origin Bitcoin Index Fund I, the fund may boost the investing behemoth’s assets under management (“AUM”), which presently stand at $8.3 trillion.

Fidelity has been an early supporter of crypto assets. The company began mining Bitcoin (“BTC”) and ether (“ETH”) in 2014 to develop knowledge of the technology, a venture that turned out to be quite profitable (http://ccw.fm/XVuYr).

Second on Keim’s list was this headline: Semtech and Helium Expand LoRaWAN Network Deployments (http://ccw.fm/uFy5P). The collaboration between Semtech and Helium has taken a step forward.

Semtech is the developer of the LoRaWAN (Long Range Wide Area Network) protocol, designed to wirelessly connect battery-operated “things” to the internet. Helium is creator of the LongFi technology, said to have a range 200 times that of Wi-Fi. The company has also developed the People’s Network, the world’s first peer-to-peer wireless network for low-power Internet of Things (“IoT”) devices to connect to the internet. With this partnership, IoT applications have now become a great deal more feasible.

Finally, a news headline that shows managers of the U.S. Postal Service are no Luddites: US Rep. Darren Soto Is Excited about the Recent USPS Blockchain Voting Patent (http://ccw.fm/hqAaP). USPS has filed a patent for mail-in voting that draws on blockchain cryptographic security safeguards. The initiative comes at a time when new allegations that mail-in voting is vulnerable to fraud have surfaced.

However, senior law-enforcement figures have expressed the view that it would be “extraordinarily difficult” for fraudulent mail-in voting to take place on a scale that would affect election results, “given the range of processes that would need to be affected or compromised by an adversary.” (http://ccw.fm/lUQc1). With Russia’s election meddling an ongoing threat, this is a decidedly reassuring pronouncement.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit http://ccw.fm/LcK2Z.

This news brief highlighted the collaboration between these two pioneers that makes it possible for registered investment advisers (“RIAs”) to offer their clients exposure to digital assets, which provides two immediate advantages: Clients’ portfolios can benefit from the continuing upturn in those assets, and clients enjoy a further measure of diversification to their holdings, thus reducing overall risk. Blockchange is a digital asset investing platform for professional wealth managers. Gemini is a cryptocurrency exchange and custodian that allows customers to transact in more than 20 cryptocurrencies, including Bitcoin, Bitcoin cash, ether, litecoin and Zcash.

Next in line was the report that TRON and Waves are partnering on Inter-chain DeFi with Gravity (http://ccw.fm/tdyMj). This partnership between TRON and Waves means that the smart-contract languages of the two platforms will be integrated, which, among other things, will counter fragmentation in the digital asset space. Waves is a blockchain platform on which users can create their own new custom tokens for use in loyalty programs, as in-app currencies and for initial coin offerings (“ICOs”). TRON is a widely used blockchain platform that is particularly well suited to the development of decentralized applications (“DApps”).

Keim’s updates ended with a reassuring news headline for crypto skeptics: The Crypto Phenomenon Cannot Be Ignored, Says US Banking Regulator (http://ccw.fm/mMmoA). Brian Brooks, acting Comptroller of the Currency (“OCC”), is seeing crypto moving further into the mainstream. His take on the crypto scene comes as no surprise. About a month ago, a directive from Brooks made it possible for banks to offer cryptocurrency custody services. The OCC is an arm of the Treasury Department, which charters, regulates, and supervises national banks, federal savings associations and agencies of foreign banks.

“The crypto phenomenon cannot be ignored, especially in a world where 50 million American citizens hold cryptocurrencies and many more millions outside the U.S,” said Brooks. “Lot of people have this stuff, and they have it for good reasons. And we need to make sure it’s accessible to them in the same safe and sound way that they can get the check in their account.”

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit http://ccw.fm/gZnPc.

Next up, was the news that Coinbase now allows Bitcoin, Ethereum, and XRP holders to pay for goods directly from their accounts (http://ccw.fm/9QCwI). Coinbase, a large cryptocurrency exchange, has partnered with BitPay, the Bitcoin payment service provider, to allow crypto holders to become crypto consumers. The integration of the two companies’ APIs will allow Coinbase users to “spend bitcoin, ether, XRP, USD Coin and other major cryptocurrencies to pay for goods offered by BitPay-supported merchants, which include Microsoft, Twitch and the Dallas Mavericks.”

Keim’s final feature showed that transacting in Bitcoin has become part and parcel of everyday life: one million Bitcoin wallets are now being used every day (http://ccw.fm/j3zM3). It appears that Bitcoin use has risen, once again, to levels not seen since late 2017. At that time, the cryptocurrency was trading at around $20,000. Bitcoin transaction levels tend to correlate positively with its price, but only since 2018, says Glassnode, the Bitcoin analytics firm that examined the data. Other factors — including increasing awareness and the potential to be a hedge against inflation — have historically influenced transaction volume, as indicated by the number of active addresses.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit http://ccw.fm/JE1OD

Keim’s second headline looked at how one company is responding to inflation expectations: “Nasdaq-Listed MicroStrategy, Wary of Looming Dollar Inflation, Turns to Bitcoin and Gold” (http://ccw.fm/gSqL9). MicroStrategy, a Nasdaq-listed provider of business intelligence, mobile software and cloud-based services, plans to invest $250 million of its cash reserves in Bitcoin, gold and other alternative assets over the next 12 months as a hedge against U.S. dollar inflation. The company’s CEO says it makes sense to “shift our treasury assets into some investments that can’t be inflated away.”

Finally, the news that a basic “banking product” will soon be available should bring cheer to the crypto community; this headline read “Genesis Partners with Luno to Create Alternative Savings Products, Extending Institutional Crypto Interest Rates to 4 Million Global Consumers” (http://ccw.fm/zICVV). Genesis, which provides digital-currency, prime-brokerage services, is joining forces with cryptocurrency exchange Luno to offer customers of the latter opportunities to earn interest on their crypto holdings. Earning interest on deposits is a defining characteristic of the established banking system. With this development, crypto has moved closer to convention.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit http://ccw.fm/cG3Oz

Celsius offers its “community of HODLers,” or long-term owners of crypto assets, a convenient way to obtain some liquidity without having to dispose of any assets. The company provides loans of stable coins and fiat money using crypto assets as collateral. An additional benefit of this arrangement is that crypto owners avoid having to pay capital gains taxes, since no assets are sold. Access to such loans has now become easier after the announcement that “every asset accepted in the Celsius Network wallet will also be approved for loan collateral.” These loans can be backed by 26 different cryptocurrencies, including “stablecoins like TUSD, PAX, USDT, and GUSD, [and] altcoins such as DASH, ZRX, XLM, and for the first time the [Celsius] native token, CEL.” The facility is available in more than 200 countries with affordable rates that start at just under 1% APR.

Keim’s second report featured speculation by Heath Tarbert, who heads the Commodity Futures Trading Commission (CFTC), that “a ‘large part’ of financial system could end up in blockchain format” (http://nnw.fm/j4jWv). The CFTC chairman marveled at the speed of development in the crypto space, noting that while the present financial system took several hundred years to evolve, the digital asset space has become a viable economic system within a decade.

Finally, a blurb for Bitcoin from Wall Street touted this: Major Investment Bank Recommends Bitcoin Over Gold (http://nnw.fm/auX1F). A senior analyst at investment bank Oppenheimer thinks that Bitcoin has potential for more appreciation than gold. At around $11,594, the cryptocurrency is a far way from its lofty levels at the end of 2017, while gold, hovering around $2,000, is at a 20-year high.

To view the most recent episode of the Wild West Crypto Show, now on TV in 45 cities across the nation, including its ongoing segment from CryptoCurrencyWire featuring the latest news from around the world, visit http://nnw.fm/pXqhx.

In other news, Keim reported MasterCard’s increasing commitment to cryptos with the press release title: MasterCard Accelerates Crypto Card Partner Program, Making It Easier for Consumers to Hold and Activate Cryptocurrencies (http://ccw.fm/TlRua). The card network, the second largest after VISA with a 30% market share, is actively recruiting cryptocurrency companies to join its Accelerate program for crypto-card issuers. Additionally, the network is collaborating with London-based, crypto-payment-processor Wirex, which makes the latter “the first ‘native’ cryptocurrency platform to gain principal membership.” The alliance allows Wirex to directly issue crypto payment cards. Now Wirex customers can top up their fiat currency designated payment cards using cryptocurrencies.

Keim’s final report — Banks in US Can Now Offer Crypto Custody Services, Regulator Says — shows that banks have found a safe way to get into the crypto space (http://ccw.fm/EpsuD). The Office of the Comptroller of Currencies, a major U.S. bank regulator, has given nationally chartered banks the green light to hold digital assets for their clients. On July 22, a senior official of the agency wrote a public letter stating that the OCC will allow banks to hold the unique cryptographic keys for a cryptocurrency wallet, opening the way for banks to provide electronic safety boxes for crypto customers. This development is one more indication that crypto adoption is continuing at rapid pace.

For the most recent episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/USLFE.

The CoinPayments platform allows merchants to accept Bitcoin and hundreds of altcoins in their stores by incorporating plugins, APIs and POS interfaces. As a result, the company, now with more than 2.2 million users in 182 countries around the world, has come a long way since 2013, when it became the first payment processor to support altcoins. CoinPayments now supports transactions in more than 1,900 coins.

Next on Keim’s list was the news that Jack Dorsey’s Cash App is sponsoring NASCAR driver Bubba Wallace (http://ccw.fm/IvaiL). Wallace, perhaps best known for the role he played in getting NASCAR to ban displays of the Confederate flag at its events, has a new backer, and it’s none other than Twitter co-founder and CEO, Jack Dorsey.

The sponsorship deal requires Wallace’s car to sport the logo of Cash App, the mobile payments platform from Square, which was also founded by Dorsey, as well as the Bitcoin emblem. Square’s Cash App offers mobile banking services plus the ability to transact in stocks and Bitcoin.

Finally, Keim reported on what is driving institutional interest in cryptocurrency investment, according to Huobi Global (http://ccw.fm/NSSEs). Huobi has experienced a surge in transactions as institutional investors have flocked to the company’s futures market place. In early May, futures and swap trading transaction volume reached $5.2 billion. A substantial part of this was due to perpetual contract swaps that hit $2.2 billion during one 24-hour period, a remarkable achievement considering that perpetual swaps were launched on March 31.

For the most recent episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/CpbTi.

Pocket Network is a decentralized infrastructure platform for the development of peer-to-peer applications. Algorand’s involvement means that developers will have easier access to the platform, which, by virtue of being decentralized, should reduce costs, improve scalability and security, and provide a wider range of blockchain development tools. Algorand is the world’s first open-source, permissionless, pure, proof-of-stake blockchain protocol.

Next Keim reported on developments in the crypto-mining space: “HIVE Blockchain Continues Increasing Bitcoin Mining Power Through Additional Purchase of Next-Generation Miners for Green Energy-Powered Quebec Facility” (http://ccw.fm/oXeVl).

HIVE Blockchain Technologies plans to add 200 Bitmain Antminer S17e 60 Terahash per second (TH/s) SHA 256 mining machines to its Quebec operations, adding to the 750 Bitmain S17+ Antminer machines previously acquired. HIVE also owns digital-currency mining facilities in Sweden and Iceland. The company focuses primarily on the production of Bitcoin and Ethereum.

Finally, security software superstar John McAfee is back in the news, after launching the world’s first private cell phone data service (http://ccw.fm/yB18m). McAfee claims his Ghost Cell Phone Data Service will be the first 4G data service to make connections to the network untraceable.

The phone will employ a software SIM instead of a physical one. A special network will deploy a range of cryptographic techniques to ensure that connections can’t be tracked. The system will support VOIP and other IP-based communication platforms. McAfee is inviting members of the media to beta test the service, which he plans to launch globally in September. McAfee is something of a curiosity in Silicon Valley, at least partially because he has orchestrated two unsuccessful presidential campaigns.

For the latest episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the most recent news from around the world, visit http://ccw.fm/NN96V.

Allen talked at length about his project, a collaboration of Cointelegraph’s BlockShow and the popular San Francisco Blockchain Week. Scheduled for July 6–10, the Unitize Decentralized Digital Conference delivered content continuously to audiences on a near-daily basis (http://ccw.fm/CSdeP). The event offered participants a chance to hear expert speakers on crypto and blockchain, as well as visit virtual exhibitions, interactive lounges and chat rooms. Networking was never so easy. An audio stream was available, so those who couldn’t take part fully still had a way to participate.

Speakers included the Hon. Hester Peirce, SEC commissioner; Vitalik Buterin, creator of Ethereum; Silvio Micali, Turing-Award cryptographer and founder of Algorand; Tim Draper, founder of DFJ VC; California Senate Majority Leader Robert Hertzberg; and Alessandro Chiesa, an assistant professor at UC Berkeley and co-founder of Zcash & StarkWare.

During his segment on the show, Tate explained how his crypto payments platform is helping small businesses expand the range of payment options they offer their customers (http://ccw.fm/j5Ebd). ForumPay can be integrated into an online merchant’s standard payment solution in only a few easy steps. The platform is a good way for online retailers to increase their customer base, as more and more people are paying for goods and services with cryptocurrencies.

Keim launched his triplet of updates with the headline “Curv Raises $23M Series a Round; Launches tX to Accelerate Institutional Adoption of Digital Assets” (http://ccw.fm/iea7p). Curv, a start-up that provides crypto custody services to institutions, has developed a platform to manage digital assets. The company’s security technology allows cryptofinance products to be safely stored and transferred on a blockchain. News of the funding was accompanied by announcement of the launch of a community of cryptographers and engineers — tX — who use Curv’s keyless technology.

In other news, Keevo announced a strategic partnership with Iron Mountain to protect crypto currency users and their heirs (http://ccw.fm/5uCsi). Keevo, which has developed a crypto hardware wallet, has formed an alliance with Iron Mountain (NYSE: IRM) to provide storage and information-management services to users of its wallet. Securing cryptocurrencies and other crypto assets has become increasingly challenging as their adoption has grown. For instance, in just the first half of 2019, more than $4 billion worth of cryptocurrencies disappeared, victim to the machinations of hackers.

Finally, Keim reported on a $2.8 billion fake-gold bullion scam (http://ccw.fm/yMjVO). Kingold Jewelry (NASDAQ: KGJI), a Chinese manufacturer of jewelry based in Wuhan, has been accused of putting up fake gold as collateral for $2.8 billion in loans the company received over the past five years. It seems the old saw — all that glitters is not gold — has been proven right once again.

For the most recent episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/bdM58.

Starting in June, KuCoin will allow its customers to buy cryptocurrencies, including Bitcoin, Ether and Tether, using U.S. dollars from their PayPal accounts. This development adds another fiat currency that KuCoin will accept as payment for transactions on its platform. The KuCoin P2P Fiat Market already supports payments made in the Canadian dollar (“CAD”), Chinese yuan (“CNY”), Indonesian rupiah (“IDR”) and Vietnamese dong (“VND”). Founded in 2017, KuCoin is a crypto exchange with one out of four crypto holders worldwide and an estimated 5 million users across 207 countries.

Next on Keim’s list was the LATOKEN VCTV Weekly Announcement (June 8–12) (http://ccw.fm/B9cN0). LATOKEN VCTV is a broadcast platform focused on the venture capital (“VC”) industry. The broadcast regularly features discussion panels, road shows, pitch competitions, keynote addresses and a variety of other VC-related content, and is widely watched by the VC community.

LATOKEN VCTV’s Weekly Announcement gives a heads-up on the agenda for the forthcoming week. The week June 8–12 began with an address by Giampaolo Parigi, chairman of a single family office discussing how to raise capital in the new normal. Other segments included a talk on how to get tech-style growth from old-economy businesses by Callum Laing, founder and CEO of MBH Corporation, and an online road show with the theme: Investments and Pivots during Pandemic: AI, Machine Learning  and Data.

Keim’s final report was the news that BitPay has been selected as Frost & Sullivan’s Company of the Year in the Alternative Payments space (http://ccw.fm/Z8yV5). BitPay is the world’s largest provider of Bitcoin and cryptocurrency payment services. The company was founded in 2011 and is notable for a number of achievements. In 2016, it launched the BitPay Visa Prepaid Debit Card, the first prepaid Visa debit card for Bitcoin. And in 2018, it received a virtual currency license from the New York Department of Financial Services.

For the most recent episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/EO3bO.

Second up was the news that “Binance Charity Pioneers COVID-19 Relief with First-Ever Fully Transparent Campaign” (http://ccw.fm/mZ64t). The Binance Charity Foundation, the philanthropic arm Binance, the world’s largest cryptocurrency exchange, is providing a large quantity of personal protective equipment (“PPE”) to New York City. This initiative follows similar ones designed to support hospitals in a number of countries ravaged by COVID-19, including China, Italy and Spain.

The relief effort in New York City was marked by the creation of a social impact cryptocurrency, christened the PPE Token, which means donors can track how their funds are put to use, something they would be hard-pressed to do with a regular charity. In its first deployment, the PPE Token is killing two birds with one stone. Not only has it verified the successful, tamper-proof delivery of 200,000 N95 masks to 11 benefiting hospitals in New York City and the surrounding region, but it has served as a form of compensation for the couriers involved.

Last but certainly not least, the news that “Blockchain Heroes Collectible Digital Trading Card Set to Feature 50 Original Superheroes on WAX Blockchain” will give many adults the chance to act out some adolescent fantasies (http://ccw.fm/zLj9x). The new set of trading cards is based on the following question: What if there existed an alternate universe in which the inventors, investors, supporters and evangelists of blockchain were actually superheroes fighting for the virtues of decentralization, privacy, transparency and freedom?

According to the release: “Blockchain Heroes, an exciting collectible digital trading card set on the WAX blockchain, will make this alternative universe a reality in August 2020. Fifty unique superheroes in a variety of card rarities will be revealed in purchasable card packs. Similar to physical collectible trading cards, each pack of digital collectibles will be randomized and provide unknown surprises. With 50 total heroes, each pack of cards will have the chance to reveal common, uncommon, rare, epic, legendary or mythic versions of any hero in increasing rarity, each with its own special design.” One wonders, could Satoshi Nakamoto be one of those superheroes?

For the most recent episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/2RZ5a

Legal agreements, for example, are as old as Methuselah but now, by incorporating blockchain technology, they are being reincarnated as “smart contracts” — self-executing, self-enforcing agreements that don’t require costly, arduous execution or resolution processes. Smart contracts are similar to regular contracts, except that the contract terms are coded in a programming language and that code is enclosed in a blockchain. Some well-known blockchain protocols, such as Bitcoin, support smart contracts. But the one mostly widely used is Ethereum, which has its own smart contract language called Solidity. Other languages used for smart contracts include C++, Java and JavaScript.

But, says Blockstack founder Dr. Muneeb Ali, such languages are insecure because they are “undecidable.” So in collaboration with Dr. Silvio Micali, founder of Algorand, Ali has launched an independent, open-source project to support Clarity, the “first-of-its-kind smart contract language” (http://ccw.fm/J7tXt). Clarity is a “decidable” language, which means that “developers can know, with mathematical certainty, what a program will and will not do ahead of time.” Now that the value of smart contracts has crossed a billion dollars, it’s time for “smart contract languages that are more safe, secure, and predictable in order to mature the industry beyond its current state,” say Ali and Micali.

In another news release — “Coca-Cola Amatil Vending Machines Accept Bitcoin via Centrapay” — one of the global beverage company’s largest bottlers is giving its customers the option to pay with cryptocurrency (http://ccw.fm/ZUk5s). Coca-Cola Amatil is partnering with digital asset integrator Centrapay to offer the service to its customers, who can use their Sylo Smart Wallet at any one of Coca-Cola’s 2,000-plus vending machines with a QR code payment sticker. Coca-Cola Amatil is the largest bottler and distributor in the Asia Pacific region, serving an estimated 270 million consumers and supporting some 140 brands.

Finally, the news that the National Science Foundation (NSF) is funding KRNC Blockchain to upgrade the U.S. dollar indicates the Feds have joined the crypto bandwagon (http://ccw.fm/Pqps1). The NSF is a federal government agency and the protocol it is funding — KRNC — could eliminate the need for private cryptocurrencies. KRNC allows existing electronic dollars to be retrofitted with new cryptographic features, including digital scarcity and smart contracts. “KRNC takes the positives of Bitcoin and adds them to money the public already owns,” said Clint Ehrlich, the project’s chief scientist. “It’s the virtual equivalent of taping gold to everyone’s dollar bills.”

For the latest episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the most recent news from around the world, visit http://ccw.fm/nMDe9

Keim started his trio of notable press reports with the news that Bitcoin IRA has released a new infographic to coincide with Bitcoin’s halving in May (http://ccw.fm/Vfm45). Founded in 2015, Bitcoin IRA acts as a custodian for Bitcoin held in self-directed Individual Retirement Accounts (IRA’s). Investor interest in adding Bitcoin (“BTC”) to IRA and 401(k) accounts has been on the increase, particularly in April and May as the cryptocurrency approached and underwent halving.

The infographic published by Bitcoin IRA shows why. After previous halvings, BTC has appreciated markedly. After the first halving in 2012, BTC price rose by 8,189%; in 2016, following the second halving, the value rose by an another 2,237%. Despite the uncertainty of present economics, many investors expect that the value of BTC will once again increase after the latest halving.

Next on Keim’s agenda was the headline that OKEx expects to double its employee count over the next two years (http://ccw.fm/Cy3lM). OKEx is said to be the largest and most diverse cryptocurrency marketplace in the world, offering facilities to trade spot in major cryptocurrencies, as well as in a range of crypto derivatives that include futures and options. The company is also launching a mentorship program in Europe. Christened the OKEx Beacon Program, the scheme will enlist six persons for a one-month exclusive mentorship with CEO Jay Hao and director of financial markets Lennix Lai.

Finally, International Spirits & Wellness Holdings (OTC: ISWH), a global brand-management holdings company, has announced it’s getting into the cryptocurrency mining business (http://ccw.fm/51sIs). The company is joined forces with Bit5ive LLC, a global leader in cryptocurrency mining and innovative turnkey mining solutions. The two companies are eyeing the Bitcoin technology market, valued at $293.66 million in 2019 and expected to reach $477 million by 2025.

For the latest episode of the Wild West Crypto Show, which includes CryptoCurrencyWire’s ongoing segment featuring the most recent news from around the world, visit http://ccw.fm/nMDe9.

South Korea’s largest chaebol is ahead of the curve, as usual, as an intriguing headline – ‘Samsung Elevates Data Protection for Mobile Devices with New Security Chip Solution’ – demonstrates (http://ccw.fm/ZHD9m). The group’s semiconductor division, Samsung Electronics, has developed a cybersecurity protection system that employs a dedicated chip. Typically, cybersecurity defenses are software solutions. The product is made up of a Secure Element (SE) chip combined with enhanced security software, which offers protection for tasks such as booting, isolated storage, mobile payment and other applications. The security chip is Common Criteria Evaluation Assurance Level (CC EAL) 6+ certified, the highest level possible for a mobile component.

Bitcoin dominance is not just in the cryptocurrency arena. Traditional financial services are giving ground to its rapidly growing sway, as Forbes reported in a piece with a lengthy label: ‘Exploding Past $10 Billion, Interest Income and Lending Are Bitcoin’s First Killer Apps’ (http://ccw.fm/96wKP). A vibrant industry has developed around deposits and loans of cryptocurrencies, similar to how traditional banks operate.

The reasons are obvious. Cryptocurrency owners can park their holdings at institutions such as Genesis Capital and Celsius and earn as much as “8.1% annual percentage rate (APR) on their first deposited Bitcoin (BTC),” all while it would be difficult to find a fixed deposit that offers an APR over 2% with traditional fiat currency (http://ccw.fm/Y3u5V). There are benefits for borrowers, as well. They have the opportunity to receive cash without having to dispose of their crypto assets, which means that they not only retain exposure but avoid the capital gains taxes that selling would trigger.

Bitcoin was featured once again in the final news item: ‘Bitwage Rolls Out Bitcoin 401(k) Plan with Help from Gemini’ (http://ccw.fm/tA1MY). Bitwage, which offers crypto payroll services, launched its bitcoin 401(k) employee pension account. The company plans to start offering the product to businesses that are struggling to meet the 75% payroll requirement in the federal Paycheck Protection Program (PPP). To date, some $660 billion has been channeled to small businesses under the PPP established by the CARES Act. The program is meant to reduce layoffs as the economy falls into a possible corona virus-induced recession.

For the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/8k6rI

First up in Keim’s update was the news that the Crypto.com Visa card program received a green light in Canada (http://ccw.fm/PI0oq). Crypto.com started life as Monaco, a company offering a cryptocurrency-funded Visa debit card. Now, after a rebranding, the company will be known as the Crypto.com MCO platform and will offer the MCO Visa card, which links Visa cards with cryptocurrency accounts. The integration allows users to easily spend their cryptocurrency on everyday purchases, wherever Visa is accepted – and Visa is everywhere. The card network is the largest in the world, with more than 40 million merchants and 336 million cardholders.

Next up, Keim shared the news release ‘Huobi Rebrands Its Derivatives Exchange as Crypto Derivatives Surge in Popularity’ (http://ccw.fm/UZ7Fg). Headquartered in Singapore, Huobi is a cryptocurrency exchange that has been offering a variety of derivative products. The rebranding has been prompted by increased interest in crypto-derivative products such as futures, forwards, swaps and options, from both large institutional and smaller retail investors. Now called Huobi Futures, the exchange’s coin-margined, perpetual contracts have experienced a surge in trading since their launch in late March, already topping the market in cumulative trading volume. On May 12, the total 24-hour, coin-margin perpetual trading volume on Huobi Futures rose above $5.46 billion, outperforming by far the exchange’s closest competitor.

Keim completed his round-up with the headline ‘World’s Leading Crypto Payments Processor CoinPayments Announces Strategic Partnership with Shopify’ (http://ccw.fm/Dt066). This collaboration, much like the MCO Visa card project, has the potential to markedly increase adoption of cryptocurrencies.

“Under the terms of the partnership, CoinPayments will now be a visible payment option for merchants on the Shopify platform and will make cryptocurrency transactions easier and more accessible while reducing transaction fees,” the announcement stated. “Vendors will now get paid faster in any of the 1,800 cryptocurrencies supported by CoinPayments while gaining access to untapped markets globally. This partnership further enables cross-border payments, allowing merchants to eliminate the hassle of working with multiple payment processors across different jurisdictions.”

For the latest episode, which includes CryptoCurrencyWire’s ongoing segment featuring the latest news from around the world, visit http://ccw.fm/t3ozS

The two crypto cowboys are dedicated to keeping viewers in the loop in a calm, collected way. Jonathan Keim, communications director of CryptoCurrencyWire, showed up with his usual trifecta of news items.

This is the third time bitcoin has halved. The cryptocurrency has been programmed to do exactly that each time another 210,000 blocks are added. The first halving took place in 2012, taking the block reward to 25 BTC, down from its original 50 BTC. In 2016, the second halving reduced the reward even further to 12.5 BTC. Now, after the latest halving, a block reward is just one-eighth of what it was when the first bitcoin block was mined in 2009. The immediate effect is that some mining operations may become unprofitable. If those miners cease operation, the supply flow of bitcoin is likely to fall, at least in the short term.

Keim kicked off his reporting with the news that the Stellar Development Foundation has invested $5 million in Abra, a global-investment platform that allows users in more than 150 countries to transact in over 100 different cryptocurrencies via a single app (http://ccw.fm/a2Mg8). The collaboration with Stellar, a fast, scalable, distributed ledger-based network, has advantages for both parties. Abra will be able to utilize Stellar as its blockchain backend, while the Stellar network will now feature a wider range of services.

The review that followed – ‘Noncustodial Crypto Investing App Ember Fund Raises $700K Via Crowdfunding Sale’ – shows that the crypto space is gaining increasing acceptance from the feds (http://ccw.fm/xWK5c). Ember Fund plans to use the funds on “customer acquisition and building out the smart contract technology that powers the Ember app.” The offering was made on the Republic investment platform and took the form of ‘Crowd SAFE’ (Simple Agreement for Future Equity) securities, which can be converted into equity at some triggering event, such as an IPO or an acquisition by a strategic buyer.

Keim’s final report – ‘American Express and Credit Suisse Execs Join Blockchain Firm BlockFi’ – was a real eye-opener, as it showed how adoption of crypto is increasing (http://ccw.fm/sAl1i). Wittney Rachlin, formerly of American Express, where she grew the business-card vertical by some 20%, has joined BlockFi as chief growth officer, while David Olsson has joined the company as global managing director of European and Asian markets. Previously, Olsson headed a Credit Suisse private banking team focused on ultra-high net-worth clients.

Jonathan Keim, communications director of CryptoCurrencyWire, popped in with another trio of interesting headlines, starting with ‘11 Lawmakers Urge US Treasury to Consider Blockchain for COVID-19 Relief’. In summary, a bipartisan group of legislators have penned a letter to Treasury Secretary Steven Mnuchin noting that blockchain and distributed ledger technologies were secure “new mechanisms” for moving money quickly and transparently, which could in turn boost liquidity in distributing funds via the federal CARES Act. If utilized, these new mechanisms would not only deliver financial relief to individuals and small businesses but help America retain its technological advantage (http://ccw.fm/nNC0Y).

Second on Keim’s list was the news that ‘Nasdaq Is Using R3’s Corda for Managing Digital Assets’. Nasdaq has collaborated with R3 to offer a platform for digital asset marketplaces on the Corda blockchain. This platform allows participants in the capital markets to use Corda in the issuance, trading, settlement and custody of digital assets (http://ccw.fm/2W7cv).

Corda is a distributed ledger technology with a difference. Unlike other blockchains that require the consensus of all nodes, a condition that slows the addition of blocks, Corda only requires consensus between the two parties effecting a transaction. This speeds up processing and makes Corda more amenable to payments platforms. To mitigate the ‘trust risk’ caused by this two-party consensus arrangement, users of the mainnet are vetted by the host. Thus, Corda is best suited for private rather than public blockchains.

Finally, the general populace is warming up to bitcoin. New data shows that bitcoin addresses with “at least 0.1 BTC’ are increasing rapidly (http://ccw.fm/cQv8w). By April 27, the number of these addresses had climbed to 3,010,784. There is a suggestion that remarks by Federal Reserve Chairman Jerome Powell may be partly responsible. In mid-February, Powell warned that the low-interest-rate environment may limit the central bank’s ability to support the economy during a downturn (http://ccw.fm/vj1sJ).

As always, the weekly news update with Jonathan Keim, communications director of CryptoCurrencyWire, was a central feature of the show. First up was news of a recently released study on blockchain that highlighted two challenges – lack of awareness and scalability – that the technology must overcome (http://ccw.fm/blQE6). Despite these caveats, further development of distributed ledger applications continues to proceed, as the next item demonstrates.

“Bitcoin ATMs pump to over 7,500 worldwide,” the news proclaims (http://ccw.fm/Mm4K1). Bitcoin ATM installation has climbed by around 70% over the past year, bringing the estimated total of ATMs to 7,500, two-thirds of which are in the United States. The pace of installation picked up this year, with approximately 1,200 units, or 16% of the total, being installed this year. This is a decidedly rapid increase. It took four years, from 2014 to 2018, for the number of bitcoin ATMs installed globally to reach 2,000.

Finally, our communications director covered a headline that shows how the industry is taking the fight to the coronavirus: ‘Virtual Blockchain Week Partners with Binance Charity to Donate Funds to Crypto Against COVID Campaign’ (http://ccw.fm/KfE25). Event organizers of Virtual Blockchain Week joined forces with Binance Charity, a nonprofit organization founded by Binance, to raise funds for the charity’s campaign, Crypto Against COVID. Donations will be used to purchase medical supplies from vetted suppliers to support hospitals and first responders around the world who are risking their lives to tackle this virus.

Keim started things off with the news that Grayscale Investments has announced its strongest quarter ever, with half a billion dollars raised in first quarter 2020 (http://ccw.fm/2nqHJ). Grayscale Investments, currently the world’s largest digital currency asset manager, raised $503.7 million across its family of products, which marked the firm’s largest inflow of capital for a single quarter. The lead product continues to be shares of Grayscale Bitcoin Trust. Grayscale says most of the capital inflow, amounting to around 88%, has come from institutional investors.

Keim’s ensuing update was encapsulated in the headline ‘BitGo Continues Expansion of Services, Launches Dashboard for Managing Digital Asset Portfolio Across Wallets and Exchanges’ (http://ccw.fm/SyZp9). BitGo, the digital asset trust and security company, recently announced the acquisition of Lumina, a comprehensive crypto-native financial platform.

The first phase following the acquisition – integrating the products of the two companies – has been completed, which means that BitGo’s range of services to institutional investors has been expanded. Users will now have a dashboard for managing, accounting and tracking the entirety of their digital asset holdings and activities across wallets, exchanges and service providers.

Finally, Keim broke the news that Portis Wallet, one of the leading wallet solutions for decentralized finance, has been acquired by ShapeShift (http://ccw.fm/DiG5s). The Israeli start-up is now enhancing its noncustodial software wallet to give customers a seamless experience in crypto-to-crypto trading, as well as enabling the instant purchase of bitcoin, ethereum and USDC from a debit card. ShapeShift is one of the world’s leading self-custody crypto platforms. The acquisition merges two companies with a shared vision: the creation of an open financial system in which self-sovereignty is easy and accessible.

For his weekly update, Jonathan Keim, communications director of CryptoCurrencyWire, provided his usual three newsbreaks.

Crypto users will be happy to know that Civic Technologies, a leading innovator in digital wallet solutions, has launched the first and only noncustodial crypto wallet to offer a $1 million digital currency guarantee provided by Coincover (http://ccw.fm/D8ta6). Coincover, a provider of risk-management solutions, offers policies that protect cryptocurrencies held in online wallets against theft from hacks. The policies will be underwritten by the Lloyd’s of London insurance syndicate, Atrium.

A survey conducted by Visual Objects showed that people’s perceptions of how cryptocurrencies are used vary considerably from actual usage (http://ccw.fm/sy3Jm). Survey participants think that cryptocurrencies are mostly employed to purchase stocks (40%) and illegal items (30%), but actual cryptocurrency consumers say their purchases go primarily to food (38%) and clothing (34%), while 29% of respondents reported that they used cryptocurrencies primarily to buy stocks.

A separate survey revealed what asset classes Americans think are the safest for a retirement account (http://ccw.fm/33bpW). Naturally, cash topped the list, with one-third of all participants indicating that they viewed cash as the safest investment during uncertain times. Gold and silver were viewed as the safest by close to 17% of those surveyed, while stocks and bonds were chosen by 15.1% of participants. Just 1% of those sampled chose crypto assets. Based on those results, faith in crypto remains very low amongst the broader population.

Jonathan Keim, communications director of CryptoCurrencyWire, had, as usual, the real news. He started his weekly update with the headline that Cryptologic Corp. (CSE: CRY) had agreed to sell its 30-megawatt bitcoin mining facility. The company has decided to dispose of its crypto mining assets and is presently exploring acquisition opportunities in sectors outside of cryptocurrency mining.

The buyer, HIVE Blockchain Technologies, is a growth-oriented, TSX Venture Exchange-listed company that is building a platform it hopes will link the blockchain sector to traditional capital markets. HIVE owns state-of-the-art, GPU-based digital-currency mining facilities in Iceland and Sweden, which produce newly minted digital currencies such as Ethereum (http://ccw.fm/bp2ZB).

In Europe, crypto developments are indeed racing ahead. The Coinfield-Sologenic consortium has announced a list of 30 global securities exchanges, the assets of which are now available for tokenization (http://ccw.fm/8oNQH). Together, these exchanges trade more than 40,000 traditional assets such as stocks, ETFs and commodities. Tokenization involves the digital representation – and often the fractionalization – of securities or other assets. The process is ideal for pricey stocks such as Alphabet (NASDAQ: GOOG), currently priced at around $1,195, and Berkshire Hathaway (NYSE: BRK.A), which usually trades above $300,000.

Keim’s roundup ended with the announcement of the cryptocurrency and blockchain industry’s most ambitious virtual conference experience (http://ccw.fm/3NEda). Event organizers of the Virtual Blockchain Week, slated for April 26 to May 2, have published details of the event, including speakers. Hosted by Joel Comm and Travis Wright of the Bad Crypto Podcast, the online conference can be accessed at VirtualBlockchainWeek.com; registration is free.

Second on Keim’s list was the news that Riot Blockchain (NASDAQ: RIOT) has reported on its 2019 financial and operational highlights (http://ccw.fm/yDCF8). The company, one of the few Nasdaq-listed public cryptocurrency mining companies in the United States, has doubled down on its crypto-mining operations on the domestic front. Riot has invested in 4,000 Bitmain S17 Pro Antminers at its facility in Oklahoma City, which, since being deployed in early 2020, have resulted in an increase in the company’s fully owned hashing power capacity to approximately 248 Petahash.

Finally, the news that Crypto.com Pay has launched a new invoicing feature will, no doubt, be well received. Crypto.com, the pioneering payments and cryptocurrency platform, announced the introduction of the new invoicing features, which will allow its merchant customers to generate and send invoices to their customers who wish to pay with cryptocurrency (http://ccw.fm/Guqz0).

Another promising partnership is the one between the IOTA Foundation, a nonprofit foundation focused on distributed ledger technology (DLT) and open-source ecosystem development, and TradeMark East Africa (TMEA). The goal of the partnership is to help TMEA in its mission to improve East African trade and global competitiveness using IOTA’s distributed-ledger technology. TMEA works closely with East African community institutions, national governments, the private sector and civil society organizations to increase trade by reducing current barriers and improving business competitiveness (http://ccw.fm/T22aO).

Lastly, Chinese ecommerce behemoth Alibaba has announced that its import e-commerce platform, Koala, has updated its products to include a full-link traceability blockchain system. Now, online buyers will have access to the logistic information of the goods they purchase by scanning a QR code with Alipay (http://ccw.fm/o6Ptl).

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

 Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

This should be no surprise to the crypto community. CryptoCurrencyWire (CCW) and ELEV8 go way back, and ELEV8 was one of the first event managers with which CCW partnered. ELEV8 is set to host four major conferences in 2020, with the first in New York City, scheduled for April 14-15, 2020. Two back-to-back forums follow in San Francisco, running August 11-12 and August 12-13, 2020. To end the year, ELEV8 returns to the Big Apple for an event slated for December 8-9.

Next up, Keim reported (http://ccw.fm/r9Lch) that the ‘IMF credits CBI for Caribbean economic growth and encourages digital currency as St. Kitts and Nevis passes virtual assets bill’. The Citizenship by Investment Program (CBI) operated by the government of St. Kitts and Nevis grants citizenship to investors who contribute at least $150,000 to its Sustainable Growth Fund (SGF) or spend $200,000 purchasing real estate on the islands.

The IMF says that the CBI played a major factor in the twin-island nation’s economic growth. The IMF press notice also floated the idea that introducing a digital currency might “solidify the monetary union by raising payment’s efficiency.” St. Kitts and Nevis belongs to a monetary union – the Eastern Caribbean Currency Union – along with seven other small Caribbean states.

Finally, Keim shared a release (http://ccw.fm/6TyrP) titled ‘Bitcoin Depot Surpasses 500 ATM Mark, Making It the Largest ATM Network in the World’. Bitcoin Depot, likely the fastest-growing multi-cryptocurrency ATM network in the world, has now installed more than 500 ATMs worldwide, making it the largest blockchain ATM network in the world. Initiatives like this provide a trusted bridge between the digital and fiat worlds, Keim noted.

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

SportsCastr, the live streaming company backed by the NFL Players Association, recently announced the launch of its FanChain cryptocurrency on FanWide, a platform that helps fans find local game-watch parties for their favorite teams. As part of the launch, sports fans can now earn FanChain tokens, known as ‘FANZ’, for checking into viewing parties at thousands of sports bars across the U.S. The tokens can be redeemed for cash through SportsCastr’s FanWallet (http://ccw.fm/R6uvZ).

In other news, Grayscale has reported another record year. Grayscale, the world’s largest crypto management firm, took in a record $607 million of investment in 2019, more than its total inflows over the past six years (http://ccw.fm/0k0QG).

Finally, the news that ‘Bakkt’s consumer app is coming in 2020, and it’ll look more like PayPal than Coinbase’ should bring cheer to the crypto community. Bakkt’s consumer app will consider any form of value that is digital as digital assets, including cryptocurrencies like bitcoin. This means that the app could also support virtual goods such as loyalty reward points and equities. The possible inclusion of equity trading, a portal for merchants and a wide array of other assets would make the app closer in nature to a traditional fintech product like PayPal than a crypto-native offering that allows retailers to accept bitcoin, like Flexa (http://ccw.fm/C2d1G).

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.

According to Alicandro, two pieces of legislation are in the cards. First is the Token Taxonomy Act, which would change the taxonomy (classification) of digital tokens. If passed into law, the act would define digital tokens as a new digital asset class rather than securities, thus freeing such assets from Securities and Exchange Commission (SEC) oversight (http://ccw.fm/Ap2L6).

Second, a legislative proposal is aimed at streamlining regulation in the crypto sector. A bill – the Cryptocurrency Act of 2020 – would clarify which federal agencies are charged with regulating digital assets. The proposals would also require those agencies to educate and inform the public about any certifications, licenses and registrations required to create, trade or otherwise deal in crypto assets (http://ccw.fm/o4paO).

After Alicandro’s contributions, Jonathan Keim, communications director of CryptoCurrencyWire, joined the crew with his usual trio of exciting updates, starting with the announcement that the North American Bitcoin Conference had landed in Miami (http://ccw.fm/YKX0x). From January 15-17, many from the crypto community are congregating at the James L. Knight Center in downtown Miami to discuss the state of crypto. Conference organizer Keynote, the well-known event producer, has been promoting collaboration and community in the crypto space through its annual events since 2014.

Keim followed up by reporting that TUSC, the “gun-friendly” cryptocurrency project, has launched its new blockchain. TUSC – The Universal Settlement Coin – announced the launch of its mainnet, which is now open to public block producers. At the same time, TUSC has resumed trading on the Altilly cryptocurrency exchange (http://ccw.fm/kt6Yg).

Last but not least was the news that ‘TaxBit Raises $5 Million in Funding to Automate Cryptocurrency Tax Compliance’ (http://ccw.fm/z44Uh). The IRS is taking note of transactions in crypto assets, and this company makes things much easier for investors and traders in the space.

Whether you’re a little wet behind the ears in the world of cryptocurrency or you have been blazing the crypto trail for a while, the Wild West Crypto Show is the best podcast to hear the Good, the Bad, and the Ugly of crypto. Thanks to C-Suite, the Wild West Crypto Show has a larger audience than ever. The show is packed full of information from experts who know a thing or two about cryptocurrency. It breaks down what newcomers need to know about getting started in cryptocurrency while providing valuable insight for more experienced Crypto Cowboys. The Wild West Crypto Show is your #1 source for the latest crypto news, inside information, & exclusive interviews from the most influential people in the crypto space.